US20190330260A1 - Process - Google Patents
Process Download PDFInfo
- Publication number
- US20190330260A1 US20190330260A1 US16/470,943 US201716470943A US2019330260A1 US 20190330260 A1 US20190330260 A1 US 20190330260A1 US 201716470943 A US201716470943 A US 201716470943A US 2019330260 A1 US2019330260 A1 US 2019330260A1
- Authority
- US
- United States
- Prior art keywords
- reaction mixture
- complex alcohol
- temperature
- minutes
- alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
- C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/095—Compounds containing the structure P(=O)-O-acyl, P(=O)-O-heteroatom, P(=O)-O-CN
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/11—Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Definitions
- the invention relates to a phosphorylation process of complex alcohols, and products obtained by that process.
- Phosphorylation processes and reagents are chosen to avoid significant degradation of the compound being phosphorylated and to produce desired yields.
- reagents such as 2:2:2-trichloroethyl dichlorophosphate, di-imidazolide chlorophosphate and di-analide chlorophosphate are used under gentle conditions to avoid degradation of the compound being phosphorylated.
- reagents such as 2:2:2-trichloroethyl dichlorophosphate, di-imidazolide chlorophosphate and di-analide chlorophosphate are used under gentle conditions to avoid degradation of the compound being phosphorylated.
- such processes have been found to produce limited yields, which would not be economical or suitable for commercial purposes.
- the reagent phosphorous oxychloride is used, but the reaction typically produces a variety of by-products and hydrogen chloride. Such process may also not be commercially viable given that the reagent phosphorous oxychloride is difficult to handle.
- the reagent P 4 O 10 which is commonly known as phosphorus pentoxide, but has other names such as phosphorus (V) oxide, phosphoric anhydride and diphosphorus pentoxide, is a white crystalline solid.
- This reagent has been used for phosphorylation of ethanol and other short chain primary alcohols (i.e. less than 6 carbon atoms) and it has been found to be suitable for phosphorylation of alcohols such as primary fatty alcohols, secondary alcohols and aromatic alcohols.
- 200043870 describes a process, which involves forming an intimate mixture of one or more of these alcohols and P 4 O 10 , partly hydrated P 4 O 10 or a mixture thereof, at a temperature below 80° C., and allowing the intimate mixture to continue to react for a period of time at this temperature, i.e. below 80° C., until formation of the phosphorylated alcohol is substantially formed. It is clear that the temperature must be kept to a minimum and below 80° C. to avoid degradation.
- the present inventors have found that complex alcohols can be phosphorylated at a high temperature and that, at such temperatures, desirable yields can be obtained with minimal degradation of the complex alcohols.
- the invention relates to a process for phosphorylating a complex alcohol, comprising the steps of:
- the complex alcohol may be a linear or branched alcohol comprising at least 6 carbon atoms (i.e. 6 or more carbon atoms). In some embodiments, the complex alcohol comprises at least 7 carbon atoms. In other embodiments, the complex alcohol comprises at least 8 carbon atoms. In particular embodiments, the complex alcohol comprises at least 10 carbon atoms.
- the number of carbon atoms mentioned herein refers to the number of carbon atoms that make up the backbone of the linear or branched complex alcohol or the ring system of the cyclic complex alcohol.
- linear and branched complex alcohols include, but are not limited to, hexanol, hexan-1-ol, heptanol, heptan-1-ol, octanol, octan-1-ol, decanol, decan-1-ol, undecanol, dodecanol, 1-dodecanol, tridecanol, 1-tetradecanol, pentadecanol, cetyl alcohol, stearyl alcohol, 1-methylhexan-1-ol, 2-methylhexan-1-ol, 3-methyl-heptan-1-ol, 4-methylhexan-1-ol, 1-methylhexan-2-ol, 2-methylhexan-2-ol, 3-methyl-hexan-2-ol, 4-methylhexan-2-ol, 1-methylhexan-3-ol, 2-methylhexan-3-ol, 3-methyl-hexan-3-ol, 4-methylhexan-3-ol, 4-
- the complex alcohol may be a cyclic complex alcohol and may be carbocyclic or heterocyclic. Further, the carbocyclic or heterocyclic complex alcohol may be aromatic or non-aromatic. In some embodiments, the heterocyclic complex alcohol comprises one or more heteroatoms. In one embodiment, the heterocyclic complex alcohol comprises one heteroatom. In another embodiment, the heterocyclic complex alcohol comprises two heteroatoms. The heteroatom may be selected from the group consisting of N, O, S and P.
- the cyclic complex alcohol may also be monocyclic or polycyclic.
- the polycyclic complex alcohol may comprise 2 or more rings. In some embodiments, the polycyclic complex alcohol comprises 2 or more rings, wherein at least 2 rings are fused.
- the complex alcohol is a sterol.
- the sterol may be a phytosterol.
- the sterol is cholesterol.
- the complex alcohol is a chromanol.
- the chromanol is a tocopherol or tocotrienol.
- the tocopherol is natural, synthetic, or a combination thereof. Natural tocopherol typically comprises about 96% ⁇ -tocopherol and a small amount of ⁇ -tocopherol. Synthetic tocopherol, on the other hand, typically comprises about 99-98% ⁇ -tocopherol. Furthermore, synthetic tocopherol comprises a mixture of the 8 possible stereoisomers, where only 1 occurs naturally.
- the tocopherol is ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocopherol, tocopherol, or a combination thereof.
- the tocopherol comprises a-tocopherol.
- the tocopherol comprises equal to or greater than about 90% ⁇ -tocopherol.
- the tocopherol is a-tocopherol (i.e. 100% ⁇ -tocopherol).
- the complex alcohol may also be a pharmaceutical compound, an anaesthetic, or an antioxidant.
- the pharmaceutical compound is an oncology drug such as a taxane, a nucleoside or a kinase inhibitor, a steroid, an opioid analgesic, a respiratory drug, a central nervous system (CNS) drug, a hypercholesterolemia drug, an antihypertensive drug, an immunosuppressive drug, an antibiotic, a luteinising hormone releasing hormone (LHRH) agonist, a LHRH antagonist, an antiviral drug, an antiretroviral drug, an estrogen receptor modulator, a somatostatin mimic, an anti-inflammatory drug, a vitamin D 2 analogue, a synthetic thyroxine, an antihistamine, an antifungal agent, a nonsteroidal anti-inflammatory drug (NSAID) or an anesthetic.
- an oncology drug such as a taxane, a nucleoside or a kinase inhibitor, a steroid, an opioid analgesic, a respiratory drug, a central nervous system
- Suitable oncology drugs include taxanes such as paclitaxel, cabazitaxel and docetaxel, camptothecin and its analogues such as irinotecan and topotecan, other antimicrotubule agents such as vinflunine, nucleosides such as gemcitabine, cladribine, fludarabine capecitabine, decitabine, azacitidine, clofarabine and nelarabine, kinase inhibitors such as sprycel, temisirolimus, dasatinib, AZD6244, AZD1152, PI-103, R-roscovitine, olomoucine and purvalanol A, and epothilone B analogues such as ixabepilone, anthrocyclines such as amrubicin, doxorubicin, epirubicin and valrubicin, super oxide inducers such as trabectecin, proteosome
- Suitable steroids include anabolic steroids such as testosterone, dihydrotestosterone, estradiol and ethynylestradiol, and corticosteroids such as cortisone, prednisilone, budesonide, triamcinolone, fluticasone, mometasone, amcinonide, flucinolone, fluocinanide, desonide, halcinonide, prednicarbate, fluocortolone, dexamethasone, betamethasone and fluprednidine.
- anabolic steroids such as testosterone, dihydrotestosterone, estradiol and ethynylestradiol
- corticosteroids such as cortisone, prednisilone, budesonide, triamcinolone, fluticasone, mometasone, amcinonide, flucinolone, fluocinanide, desonide, halcinonide, prednicarbate, fluocor
- Suitable opioid analgesics include morphine, oxymorphone, naloxone, codeine, oxycodone, methylnaltrexone, hydromorphone, buprenorphine and etorphine.
- Suitable respiratory drugs include bronchodilators, inhaled steroids, and decongestants and more particularly salbutamol, ipratropium bromide, montelukast and formoterol.
- Suitable CNS drugs include antipsychotic such as quetiapine and antidepressants such as venlafaxine.
- Suitable drugs to control hypercholesterolemia include ezetimibe and statins such as simvastatin, lovastatin, atorvastatin, fluvastatin, pitavastatin, pravastatin and rosuvastatin.
- Suitable antihypertensive drugs include losartan, olmesartan, medoxomil, metrolol, travoprost and bosentan.
- Suitable immunosuppressive drugs include glucocorticoids, cytostatics, antibody fragments, anti-immunophilins, interferons, TNF binding proteins and more particularly, cacineurin inhibitors such as tacrolimus, mycophenolic acid and its derivatives such as mycophenolate mofetil, and cyclosporine.
- Suitable antibacterial agents include antibiotics such as amoxicillin, meropenem and clavulanic acid.
- Suitable LHRH agonists include goserelin acetate, deslorelin and leuprorelin.
- Suitable LHRH antagonists include cetrorelix, ganirelix, abarelix and degarelix.
- Suitable antiviral agents include nucleoside analogs such as lamivudine, zidovudine, abacavir and entecavir and suitable antiretro viral drugs include protease inhibitors such as atazanavir, lapinavir and ritonavir.
- suitable selective estrogen receptor modulators include raloxifene and fulvestrant.
- Suitable somastatin mimics include octreotide.
- Suitable anti-inflammatory drugs include mesalazine and suitable NSAIDs include acetaminophen (paracetamol).
- Suitable vitamin D 2 analogues include paricalcitol.
- Suitable synthetic thyroxines include levothyroxine.
- Suitable anti-histamines include fexofenadine.
- Suitable antifungal agents include azoles such as viriconazole.
- Suitable antioxidants include ascorbic acid, hydroxy carotenoids such as retinol, and calciferol.
- Suitable anesthetics include propofol.
- the complex alcohol may also be a solvent, such as, for example, tetraglycol and lauryl alcohol.
- the complex alcohol is sparingly soluble or insoluble in aqueous solution.
- the complex alcohol may be farnesol.
- the complex alcohol may be a mixture of two or more complex alcohols.
- the linear, branched or cyclic complex alcohol is monohydroxy or polyhydroxy.
- the polyhydroxy complex alcohol comprises 2 hydroxy groups.
- the polyhydroxy complex alcohol comprises more than 2 hydroxy groups.
- the polyhydroxy complex alcohol may comprise 3, 4 or 5 hydroxy groups.
- the complex alcohol is a monohydroxy complex alcohol.
- the linear, branched or cyclic complex alcohol may be unsubstituted or substituted with one or more substituent groups.
- substituted or substituteduent refers to a group which may or may not be further substituted with one or more groups selected from C 1-6 alkyl, C 1-6 alkynyl, aryl, aldehyde, halogen, haloC 1-6 alkyl, haloC 1-6 alkenyl, haloC 1-6 alkynyl, haloaryl, hydroxy, C 1-6 alkylhydroxy, C 1-6 alkoxy, —OC 1-6 alkylhydroxy, —OC 1-6 alkylC 1-6 alkoxy, C 1-6 alkenyloxy, aryloxy, benzyloxy, haloC 1-6 alkoxy, haloC 1-6 alkenyloxy, haloaryloxy, nitro, nitroC 1-6 al
- the complex alcohol is mixed with P 4 O 10 .
- the P 4 O 10 may be partly hydrated (or a polyphosphoric acid).
- the molar ratio of hydroxyl group (of the complex alcohol) to phosphorus may be within a range of about 3:1 to about 1:3. In some embodiments, the molar ratio is within the range of about 2:1 to about 1:2. In one embodiment, the molar ratio is about 2:1.
- the molar ratio is about 1:1, or substantially equimolar.
- the molar ratio of hydroxyl group (of the complex alcohol) to P 4 O 10 would be about 1:0.25.
- the process is for phosphorylating a complex alcohol, comprising the steps of:
- This step involves mixing the complex alcohol and P 4 O 10 until its exothermic reaction temperature is achieved.
- exothermic reaction is well known in the relevant art. It describes a chemical reaction that releases energy by light or, as in the present invention, heat.
- exothermic reaction temperature is used herein to refer to the temperature at which the chemical reaction between the complex alcohol and P 4 O 10 commences to release heat.
- the complex alcohol and P 4 O 10 are mixed until its exothermic reaction temperature is achieved, and may be mixed to form an intimate mixture. Mixing may be achieved by any available means, including stirring (manual or mechanical). In some embodiments, mixing may also involve the use a high-shear mixer.
- this step may also involve heating the complex alcohol and P 4 O 10 to advance the chemical reaction between the complex alcohol and P 4 O 10 to its exothermic reaction temperature.
- the complex alcohol and P 4 O 10 may be heated so that its exothermic reaction temperature is achieved in a shorter period of time.
- the complex alcohol and P 4 O 10 may be heated to advance the chemical reaction between the complex alcohol and P 4 O 10 to its exothermic reaction temperature in about 15 to 30 minutes.
- no heating is applied so that the chemical reaction between the complex alcohol and P 4 O 10 achieves its exothermic reaction temperature over the time needed to reach this temperature.
- This step involves allowing the reaction mixture of step (a) to react until the exothermic reaction is complete.
- heat is generated by the exothermic reaction process and the temperature of the reaction rises without external heating.
- the exothermic reaction is complete when the temperature of the chemical reaction between the complex alcohol and P 4 O 10 begins to fall.
- this step does not involve mixing. In alternate embodiments, this step involves mixing. As mentioned above, mixing may be achieved by any available means, including stirring (manual or mechanical), and may also involve the use of a high-shear mixer.
- This step involves heating or cooling the reaction mixture of step (b) to at least 80° C.
- the temperature is at least 80° C.
- the term “at least 80° C.” is used herein to refer to a temperature equal to or greater than 80° C. In some embodiments, the temperature is within the range of at least 80° C. to about 160° C. In other embodiments, the temperature is within the range of about 90° C. to 140° C. In one embodiment, the temperature is about 90° C. In another embodiment, the temperature is about 100° C. In yet another embodiment, the temperature is about 110° C.
- reaction mixture of step (b) will be cooled to the relevant temperature if the temperature of the reaction mixture of step (b) is higher than this temperature after the exothermic reaction between the complex alcohol and P 4 O 10 is complete.
- reaction mixture of step (b) will be heated to the relevant temperature if the temperature of the reaction mixture of step (b) is lower than this temperature after the exothermic reaction between the complex alcohol and P 4 O 10 is complete.
- the heating or cooling of the reaction mixture of step (b) may be allowed to proceed gradually over time.
- the time may be limited to a specific period of time.
- the period of time may be limited to about 30 to about 90 minutes, after which external means is used to further heat or to further cool the reaction mixture of step (b).
- the reaction mixture of step (b) may be maintained at this temperature for about 30 to about 180 minutes. In some embodiments, the reaction mixture of step (b) is maintained at this temperature for about 60 to about 180 minutes. In one embodiment, the reaction mixture of step (b) is maintained at this temperature for about 60 to about 120 minutes. In another embodiment, the reaction mixture of step (b) is maintained at this temperature for about 60 minutes.
- This step involves hydrolysing the reaction mixture of step (c).
- Hydrolysis involves the addition of an aqueous solution.
- the aqueous solution may be water (e.g. deionised water). In some embodiments, an excess amount of water is added during the step of hydrolysis.
- the reaction mixture of step (c) may be maintained at the hydrolysis temperature of at least 80° C.
- the term “at least 80° C.” has the meaning mentioned above.
- the hydrolysis temperature is within the range of at least 80° C. to about 150° C. In some embodiments, the hydrolysis temperature is within the range of about 85° C. to 120° C. In one embodiment, the hydrolysis temperature is within the range of about 90° C. to 110° C. In another embodiment, the hydrolysis temperature is within the range of about 90° C. to 100° C. In yet another embodiment, the hydrolysis temperature is within the range of about 100° C. to 110° C.
- Hydrolysis may be conducted for about 30 to about 180 minutes. In some embodiments, hydrolysis is conducted for about 30 to about 120 minutes. In one embodiment, hydrolysis is conducted for about 60 to about 120 minutes. In another embodiment, hydrolysis is conducted for about 90 to about 120 minutes. In one embodiment, hydrolysis is conducted for about 60 to about 90 minutes.
- the process may be conducted in the absence of an additional solvent.
- additional solvent is used herein to refer to a solvent other than the aqueous solution, such as water, used during the step of hydrolysis.
- the reaction is conducted without an additional solvent such that the complex alcohol and P 4 O 10 are mixed in neat form.
- the invention also relates to a product obtained by the process.
- the product obtained by the process may be a phosphorylated mono-complex alcohol, a phosphorylated di-complex alcohol, or a mixture thereof.
- the product is a mixture of a phosphorylated mono-complex alcohol and a phosphorylated di-complex alcohol.
- the molar ratio of the mixture of the phosphorylated mono-complex alcohol and the phosphorylated di-complex alcohol may be at least about 2:1, about 2:1, about 6:4 or about 8:2, or within a range of about 4:1 to about 1:4 or about 6:4 to about 8:2.
- the product obtained by the process may be a cross-coupled phosphate diester.
- the product obtained by the process may also comprise residual amounts of unreacted complex alcohol and/or related substances.
- the process may further involve purification steps.
- the product obtained by the process may also be further reacted with an amphoteric surfactant.
- the complex alcohol is a tocopherol
- the phosphorylated complex alcohol is a tocopheryl phosphate.
- the tocopheryl phosphate may be a mono-tocopheryl phosphate, a di-tocopheryl phosphate, or a mixture thereof.
- the amphoteric surfactant is a tertiary amine of the formula NR 1 R 2 R 3 , wherein R 1 is selected from the group consisting of C 6-22 alkyl, and R 2 and R 3 are independently selected from the group consisting of H, (CH 2 ) n COOX, (CH 2 ) n CHOHCH 2 SO 3 X, (CH 2 ) n CHOHCH 2 OPO 3 X, in which X is H or forms a salt with a cation selected from the group consisting of sodium, potassium, lithium, calcium, magnesium, ammonium, alkylammonium and alkanolamine, and n is 1 or 2.
- C 6-22 alkyl refers to a straight or branched chain or cyclic hydrocarbon group having from 6 to 22 carbon atoms. Examples include, but are not limited to, hexyl, cyclohexyl, decyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl and octadecyl.
- R 1 is a C 12 alkyl (dodecyl), and R 2 and R 3 are independently selected from CH 2 CH 2 COOH and CH 2 CH 2 COONa.
- the tertiary amine is 3-[2-carboxyethyl(dodecyl)amino] propanoic acid.
- the tertiary amine is 3,3′-dodecylimino)dipropionic acid monosodium salt (or lauryliminodipropionic acid, sodium lauryliminodipropionate or N-lauryl iminodipropionate).
- the product obtained by this further process may be lauryliminodipropionic acid tocopheryl phosphates or a salt thereof.
- the salt is a sodium salt.
- Synthetic ⁇ -tocopherol and P 4 O 10 were mixed (mass ratio 0.170), and with heating, the exothermic reaction temperature was reached within about 15 minutes. Heating was continued until the reaction mixture a temperature of about 120° C. was achieved and then stopped. The temperature of the reaction mixture continued to rise for a brief period of time. When the exothermic reaction was complete, the reaction mixture was allowed to cool without any external control for about 60 minutes. The reaction was then further cooled to a temperature of about 90° C. before hydrolysis was conducted with deionised water for about 60 minutes.
- the process produced about 58.52% w/w mono-tocopheryl phosphate and about 30.49% w/w di-tocopheryl phosphate.
- Synthetic ⁇ -tocopherol and P 4 O 10 were mixed (mass ratio 0.170), and with heating, the exothermic reaction temperature was reached within about 15 minutes. Heating was continued until the reaction mixture a temperature of about 120° C. was achieved and then stopped. The temperature of the reaction mixture continued to rise for a brief period of time.
- reaction mixture was allowed to cool without any external control for about 60 minutes.
- the reaction was then further cooled to a temperature of about 90° C. before hydrolysis with deionised water was conducted for about 60 minutes.
- the process produced about 59.26% w/w mono-tocopheryl phosphate and about 30.91% w/w di-tocopheryl phosphate.
- Natural ⁇ -tocopherol (0.07% w/w) and P 4 O 10 were mixed (mass ratio 0.170), and with heating, the exothermic reaction temperature was reached within about 15 minutes. Heating was continued until the reaction mixture a temperature of about 120° C. was achieved and then stopped. The temperature of the reaction mixture continued to rise for a brief period of time. When the exothermic reaction was complete, the reaction mixture was allowed to cool without any external control for about 60 minutes. The reaction was then further cooled to a temperature of about 90° C. before hydrolysis with deionised water was conducted for about 60 minutes.
- the process produced about 55.79% w/w mono-tocopheryl phosphate and about 27.68% w/w di-tocopheryl phosphate.
- Mass spectrometry analysis of the end product indicated the formation of the desired monophosphate derivative of propofol.
- Mass spectrometry analysis of the end product indicated the formation of the monophosphate derivatives of propofol and D- ⁇ -tocopherol, as well as the cross-coupled phosphate diester.
- Mass spectrometry analysis of the end product indicated the formation of the desired monophosphate derivative of lauryl alcohol.
- ⁇ -Estradiol (0.490 g, 1.80 mmol) and P 4 O 10 (0.140 g, 0.493 mmol) were combined in a Radleys 12 Station Carousel reaction tube and suspended in Triacetin (2 mL). The reaction mixture was heated at 100° C. for 60 minutes and to complete the exothermic reaction. The reaction mixture was then cooled to 90° C. before it was hydrolysed with H 2 O (1.00 g) at that temperature for 60 minutes.
Abstract
Description
- The invention relates to a phosphorylation process of complex alcohols, and products obtained by that process.
- It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country.
- Phosphorylation processes and reagents are chosen to avoid significant degradation of the compound being phosphorylated and to produce desired yields.
- In some phosphorylation processes, reagents such as 2:2:2-trichloroethyl dichlorophosphate, di-imidazolide chlorophosphate and di-analide chlorophosphate are used under gentle conditions to avoid degradation of the compound being phosphorylated. However, such processes have been found to produce limited yields, which would not be economical or suitable for commercial purposes.
- In other phosphorylation processes, the reagent phosphorous oxychloride is used, but the reaction typically produces a variety of by-products and hydrogen chloride. Such process may also not be commercially viable given that the reagent phosphorous oxychloride is difficult to handle.
- The reagent P4O10, which is commonly known as phosphorus pentoxide, but has other names such as phosphorus (V) oxide, phosphoric anhydride and diphosphorus pentoxide, is a white crystalline solid. This reagent has been used for phosphorylation of ethanol and other short chain primary alcohols (i.e. less than 6 carbon atoms) and it has been found to be suitable for phosphorylation of alcohols such as primary fatty alcohols, secondary alcohols and aromatic alcohols. Australian Patent No. 200043870 describes a process, which involves forming an intimate mixture of one or more of these alcohols and P4O10, partly hydrated P4O10 or a mixture thereof, at a temperature below 80° C., and allowing the intimate mixture to continue to react for a period of time at this temperature, i.e. below 80° C., until formation of the phosphorylated alcohol is substantially formed. It is clear that the temperature must be kept to a minimum and below 80° C. to avoid degradation.
- The phosphorylation of complex alcohols, such as secondary and tertiary alcohols, with P4O10 at higher temperatures was thought to lead to degradation and/or side reactions such as dehydration and double bond formation. These problems teach away from the use of P4O10 for the efficient and commercial phosphorylation of complex alcohols at high temperatures.
- The present inventors have found that complex alcohols can be phosphorylated at a high temperature and that, at such temperatures, desirable yields can be obtained with minimal degradation of the complex alcohols.
- Accordingly, there is provided a process for phosphorylating a complex alcohol, comprising the steps of:
- (a) mixing the complex alcohol and P4O10 until its exothermic reaction temperature is achieved;
- (b) allowing the reaction mixture of step (a) to react until the exothermic reaction is complete;
- (c) heating or cooling the reaction mixture of step (b) to at least 80° C.; and
- (d) hydrolysing the reaction mixture of step (c).
- There is also provided a product obtained by the process.
- The invention relates to a process for phosphorylating a complex alcohol, comprising the steps of:
- (a) mixing the complex alcohol and P4O10 until its exothermic reaction temperature is achieved;
- (b) allowing the reaction mixture of step (a) to react until the exothermic reaction is complete;
- (c) heating or cooling the reaction mixture of step (b) to at least 80° C.; and
- (d) hydrolysing the reaction mixture of step (c).
- The complex alcohol may be a linear or branched alcohol comprising at least 6 carbon atoms (i.e. 6 or more carbon atoms). In some embodiments, the complex alcohol comprises at least 7 carbon atoms. In other embodiments, the complex alcohol comprises at least 8 carbon atoms. In particular embodiments, the complex alcohol comprises at least 10 carbon atoms. The number of carbon atoms mentioned herein refers to the number of carbon atoms that make up the backbone of the linear or branched complex alcohol or the ring system of the cyclic complex alcohol.
- Examples of linear and branched complex alcohols include, but are not limited to, hexanol, hexan-1-ol, heptanol, heptan-1-ol, octanol, octan-1-ol, decanol, decan-1-ol, undecanol, dodecanol, 1-dodecanol, tridecanol, 1-tetradecanol, pentadecanol, cetyl alcohol, stearyl alcohol, 1-methylhexan-1-ol, 2-methylhexan-1-ol, 3-methyl-heptan-1-ol, 4-methylhexan-1-ol, 1-methylhexan-2-ol, 2-methylhexan-2-ol, 3-methyl-hexan-2-ol, 4-methylhexan-2-ol, 1-methylhexan-3-ol, 2-methylhexan-3-ol, 3-methyl-hexan-3-ol, 4-methylhexan-3-ol, 1-methylhexan-4-ol, 2-methylhexan-4-ol, 3-methyl-hexan-4-ol, 4-methylhexan-4-ol, 1-methylhexan-5-ol, 2-methylhexan-5-ol, 3-methyl-hexan-5-ol, 4-methylhexan-5-ol, 1-methylhexan-6-ol, 2-methylhexan-6-ol, 3-methyl-hexan-6-ol, 4-methylhexan-6-ol, 1-ethylhexan-1-ol, 2-ethylhexan-1-ol, 3-ethyl-hexan-1-ol, 4-methylhexan-1-ol, 1-ethylhexan-2-ol, 2-ethylhexan-2-ol, 3-ethyl-hexan-2-ol, 4-ethylhexan-2-ol, 1-ethylhexan-3-ol, 2-ethylhexan-3-ol, 3-ethyl-hexan-3-ol, 4-ethylhexan-3-ol, 1-ethylhexan-4-ol, 2-ethylhexan-4-ol, 3-ethyl-hexan-4-ol, 4-ethylhexan-4-ol, 1-ethylhexan-5-ol, 2-ethylhexan-5-ol, 3-ethyl-hexan-5-ol, 4-ethylhexan-5-ol, 1-ethylhexan-6-ol, 2-ethylhexan-6-ol, 3-ethyl-hexan-6-ol, 4-ethylhexan-6-ol, 1-methylheptan-1-ol, 2-methylheptan-1-ol, 3-methyl-heptan-1-ol, 4-methylheptan-1-ol, 1-methylheptan-2-ol, 2-methylheptan-2-ol, 3-methyl-heptan-2-ol, 4-methylheptan-2-ol, 1-methylheptan-3-ol, 2-methylheptan-3-ol, 3-methyl-heptan-3-ol, 4-methylheptan-3-ol, 1-methylheptan-4-ol, 2-methylheptan-4-ol, 3-methyl-heptan-4-ol, 4-methylheptan-4-ol, 1-methylheptan-5-ol, 2-methylheptan-5-ol, 3-methyl-heptan-5-ol, 4-methylheptan-5-ol, 1-methylheptan-6-ol, 2-methylheptan-6-ol, 3-methyl-heptan-6-ol, 4-methylheptan-6-ol, 1-methylheptan-7-ol, 2-methylheptan-7-ol, 3-methyl-heptan-7-ol, 4-methylheptan-7-ol, 1-ethylheptan-1-ol, 2-ethylheptan-1-ol, 3-ethyl-heptan-1-ol, 4-methylheptan-1-ol, 1-ethylheptan-2-ol, 2-ethylheptan-2-ol, 3-ethyl-heptan-2-ol, 4-ethylheptan-2-ol, 1-ethylheptan-3-ol, 2-ethylheptan-3-ol, 3-ethyl-heptan-3-ol, 4-ethylheptan-3-ol, 1-ethylheptan-4-ol, 2-ethylheptan-4-ol, 3-ethyl-heptan-4-ol, 4-ethylheptan-4-ol, 1-ethylheptan-5-ol, 2-ethylheptan-5-ol, 3-ethyl-heptan-5-ol, 4-ethylheptan-5-ol, 1-ethylheptan-6-ol, 2-ethylheptan-6-ol, 3-ethyl-heptan-6-ol, 4-ethylheptan-6-ol, 1-ethylheptan-7-ol, 2-ethylheptan-7-ol, 3-ethyl-heptan-7-ol, 4-ethylheptan-7-ol, 1-methyloctan-1-ol, 2-methyloctan-1-ol, 3-methyl-octan-1-ol, 4-methyloctan-1-ol, 1-methyloctan-2-ol, 2-methyloctan-2-ol, 3-methyl-octan-2-ol, 4-methyloctan-2-ol, 1-methyloctan-3-ol, 2-methyloctan-3-ol, 3-methyl-octan-3-ol, 4-methyloctan-3-ol, 1-methyloctan-4-ol, 2-methyloctan-4-ol, 3-methyl-octan-4-ol, 4-methyloctan-4-ol, 1-methyloctan-5-ol, 2-methyloctan-5-ol, 3-methyl-octan-5-ol, 4-methyloctan-5-ol, 1-methyloctan-6-ol, 2-methyloctan-6-ol, 3-methyl-octan-6-ol, 4-methyloctan-6-ol, 1-methyloctan-7-ol, 2-methyloctan-7-ol, 3-methyl-octan-7-ol, 4-methyloctan-7-ol, 1-methyloctan-8-ol, 2-methyloctan-8-ol, 3-methyl-octan-8-ol, 4-methyloctan-8-ol, 1-ethyloctan-1-ol, 2-ethyloctan-1-ol, 3-ethyl-octan-1-ol, 4-methyloctan-1-ol, 1-ethyloctan-2-ol, 2-ethyloctan-2-ol, 3-ethyl-octan-2-ol, 4-ethyloctan-2-ol, 1-ethyloctan-3-ol, 2-ethyloctan-3-ol, 3-ethyl-octan-3-ol, 4-ethyloctan-3-ol, 1-ethyloctan-4-ol, 2-ethyloctan-4-ol, 3-ethyl-octan-4-ol, 4-ethyloctan-4-ol, 1-ethyloctan-5-ol, 2-ethyloctan-5-ol, 3-ethyl-octan-5-ol, 4-ethyloctan-5-ol, 1-ethyloctan-6-ol, 2-ethyloctan-6-ol, 3-ethyl-octan-6-ol, 4-ethyloctan-6-ol, 1-ethyloctan-7-ol, 2-ethyloctan-7-ol, 3-ethyl-octan-7-ol, 4-ethyloctan-7-ol, 1-ethyloctan-8-ol, 2-ethyloctan-8-ol, 3-ethyl-octan-8-ol, 4-ethyloctan-8-ol, 1-methylnonan-1-ol, 2-methylnonan-1-ol, 3-methyl-nonan-1-ol, 4-methylnonan-1-ol, 1-methylnonan-2-ol, 2-methylnonan-2-ol, 3-methyl-nonan-2-ol, 4-methylnonan-2-ol, 1-methylnonan-3-ol, 2-methylnonan-3-ol, 3-methyl-nonan-3-ol, 4-methylnonan-3-ol, 1-methylnonan-4-ol, 2-methylnonan-4-ol, 3-methyl-nonan-4-ol, 4-methylnonan-4-ol, 1-methylnonan-5-ol, 2-methylnonan-5-ol, 3-methyl-nonan-5-ol, 4-methylnonan-5-ol, 1-methylnonan-6-ol, 2-methylnonan-6-ol, 3-methyl-nonan-6-ol, 4-methylnonan-6-ol, 1-methylnonan-7-ol, 2-methylnonan-7-ol, 3-methyl-nonan-7-ol, 4-methylnonan-7-ol, 1-methylnonan-8-ol, 2-methylnonan-8-ol, 3-methyl-nonan-8-ol, 4-methylnonan-8-ol, 1-methylnonan-9-ol, 2-methylnonan-9-ol, 3-methyl-nonan-9-ol, 4-methylnonan-9-ol, 1-ethylnonan-1-01, 2-ethylnonan-1-ol, 3-ethyl-nonan-1-ol, 4-methylnonan-1-ol, 1-ethylnonan-2-ol, 2-ethylnonan-2-ol, 3-ethyl-nonan-2-ol, 4-ethylnonan-2-ol, 1-ethylnonan-3-ol, 2-ethylnonan-3-ol, 3-ethyl-nonan-3-ol, 4-ethylnonan-3-ol, 1-ethylnonan-4-ol, 2-ethylnonan-4-ol, 3-ethyl-nonan-4-ol, 4-ethylnonan-4-ol, 1-ethylnonan-5-ol, 2-ethylnonan-5-ol, 3-ethyl-nonan-5-ol, 4-ethylnonan-5-ol, 1-ethylnonan-6-ol, 2-ethylnonan-6-ol, 3-ethyl-nonan-6-ol, 4-ethylnonan-6-ol, 1-ethylnonan-7-ol, 2-ethylnonan-7-ol, 3-ethyl-nonan-7-ol, 4-ethylnonan-7-ol, 1-ethylnonan-8-ol, 2-ethylnonan-8-ol, 3-ethyl-nonan-8-ol, 4-ethylnonan-8-ol, 1-ethylnonan-9-ol, 2-ethylnonan-9-ol, 3-ethyl-nonan-9-ol, and 4-ethylnonan-9-ol.
- The complex alcohol may be a cyclic complex alcohol and may be carbocyclic or heterocyclic. Further, the carbocyclic or heterocyclic complex alcohol may be aromatic or non-aromatic. In some embodiments, the heterocyclic complex alcohol comprises one or more heteroatoms. In one embodiment, the heterocyclic complex alcohol comprises one heteroatom. In another embodiment, the heterocyclic complex alcohol comprises two heteroatoms. The heteroatom may be selected from the group consisting of N, O, S and P.
- The cyclic complex alcohol may also be monocyclic or polycyclic. The polycyclic complex alcohol may comprise 2 or more rings. In some embodiments, the polycyclic complex alcohol comprises 2 or more rings, wherein at least 2 rings are fused.
- In particular embodiments, the complex alcohol is a sterol. The sterol may be a phytosterol. In one specific embodiment, the sterol is cholesterol.
- In other particular embodiments, the complex alcohol is a chromanol. In some embodiments, the chromanol is a tocopherol or tocotrienol.
- In some embodiments, the tocopherol is natural, synthetic, or a combination thereof. Natural tocopherol typically comprises about 96% α-tocopherol and a small amount of γ-tocopherol. Synthetic tocopherol, on the other hand, typically comprises about 99-98% α-tocopherol. Furthermore, synthetic tocopherol comprises a mixture of the 8 possible stereoisomers, where only 1 occurs naturally.
- In other embodiments, the tocopherol is α-tocopherol, β-tocopherol, γ-tocopherol, tocopherol, or a combination thereof. In particular embodiments, the tocopherol comprises a-tocopherol. In one embodiment, the tocopherol comprises equal to or greater than about 90% α-tocopherol. In another embodiment, the tocopherol is a-tocopherol (i.e. 100% α-tocopherol).
- The complex alcohol may also be a pharmaceutical compound, an anaesthetic, or an antioxidant.
- In some embodiments, the pharmaceutical compound is an oncology drug such as a taxane, a nucleoside or a kinase inhibitor, a steroid, an opioid analgesic, a respiratory drug, a central nervous system (CNS) drug, a hypercholesterolemia drug, an antihypertensive drug, an immunosuppressive drug, an antibiotic, a luteinising hormone releasing hormone (LHRH) agonist, a LHRH antagonist, an antiviral drug, an antiretroviral drug, an estrogen receptor modulator, a somatostatin mimic, an anti-inflammatory drug, a vitamin D2 analogue, a synthetic thyroxine, an antihistamine, an antifungal agent, a nonsteroidal anti-inflammatory drug (NSAID) or an anesthetic.
- Suitable oncology drugs include taxanes such as paclitaxel, cabazitaxel and docetaxel, camptothecin and its analogues such as irinotecan and topotecan, other antimicrotubule agents such as vinflunine, nucleosides such as gemcitabine, cladribine, fludarabine capecitabine, decitabine, azacitidine, clofarabine and nelarabine, kinase inhibitors such as sprycel, temisirolimus, dasatinib, AZD6244, AZD1152, PI-103, R-roscovitine, olomoucine and purvalanol A, and epothilone B analogues such as ixabepilone, anthrocyclines such as amrubicin, doxorubicin, epirubicin and valrubicin, super oxide inducers such as trabectecin, proteosome inhibitors such as bortezomib and other topoisomerase inhibitors, intercalating agents and alkylating agents.
- Suitable steroids include anabolic steroids such as testosterone, dihydrotestosterone, estradiol and ethynylestradiol, and corticosteroids such as cortisone, prednisilone, budesonide, triamcinolone, fluticasone, mometasone, amcinonide, flucinolone, fluocinanide, desonide, halcinonide, prednicarbate, fluocortolone, dexamethasone, betamethasone and fluprednidine.
- Suitable opioid analgesics include morphine, oxymorphone, naloxone, codeine, oxycodone, methylnaltrexone, hydromorphone, buprenorphine and etorphine.
- Suitable respiratory drugs include bronchodilators, inhaled steroids, and decongestants and more particularly salbutamol, ipratropium bromide, montelukast and formoterol. Suitable CNS drugs include antipsychotic such as quetiapine and antidepressants such as venlafaxine.
- Suitable drugs to control hypercholesterolemia include ezetimibe and statins such as simvastatin, lovastatin, atorvastatin, fluvastatin, pitavastatin, pravastatin and rosuvastatin.
- Suitable antihypertensive drugs include losartan, olmesartan, medoxomil, metrolol, travoprost and bosentan.
- Suitable immunosuppressive drugs include glucocorticoids, cytostatics, antibody fragments, anti-immunophilins, interferons, TNF binding proteins and more particularly, cacineurin inhibitors such as tacrolimus, mycophenolic acid and its derivatives such as mycophenolate mofetil, and cyclosporine.
- Suitable antibacterial agents include antibiotics such as amoxicillin, meropenem and clavulanic acid.
- Suitable LHRH agonists include goserelin acetate, deslorelin and leuprorelin.
- Suitable LHRH antagonists include cetrorelix, ganirelix, abarelix and degarelix.
- Suitable antiviral agents include nucleoside analogs such as lamivudine, zidovudine, abacavir and entecavir and suitable antiretro viral drugs include protease inhibitors such as atazanavir, lapinavir and ritonavir. Suitable selective estrogen receptor modulators include raloxifene and fulvestrant.
- Suitable somastatin mimics include octreotide.
- Suitable anti-inflammatory drugs include mesalazine and suitable NSAIDs include acetaminophen (paracetamol).
- Suitable vitamin D2 analogues include paricalcitol.
- Suitable synthetic thyroxines include levothyroxine.
- Suitable anti-histamines include fexofenadine.
- Suitable antifungal agents include azoles such as viriconazole.
- Suitable antioxidants include ascorbic acid, hydroxy carotenoids such as retinol, and calciferol.
- Suitable anesthetics include propofol.
- The complex alcohol may also be a solvent, such as, for example, tetraglycol and lauryl alcohol.
- In some embodiments, the complex alcohol is sparingly soluble or insoluble in aqueous solution. For example, the complex alcohol may be farnesol.
- In some embodiments, the complex alcohol may be a mixture of two or more complex alcohols.
- In the above embodiments, the linear, branched or cyclic complex alcohol is monohydroxy or polyhydroxy. In some embodiments, the polyhydroxy complex alcohol comprises 2 hydroxy groups. In other embodiments, the polyhydroxy complex alcohol comprises more than 2 hydroxy groups. For example, the polyhydroxy complex alcohol may comprise 3, 4 or 5 hydroxy groups. In particular embodiments, the complex alcohol is a monohydroxy complex alcohol.
- In the above embodiments, the linear, branched or cyclic complex alcohol may be unsubstituted or substituted with one or more substituent groups. Unless otherwise defined, the term “substituted” or “substituent” as used herein refers to a group which may or may not be further substituted with one or more groups selected from C1-6alkyl, C1-6alkynyl, aryl, aldehyde, halogen, haloC1-6alkyl, haloC1-6alkenyl, haloC1-6alkynyl, haloaryl, hydroxy, C1-6alkylhydroxy, C1-6alkoxy, —OC1-6alkylhydroxy, —OC1-6alkylC1-6alkoxy, C1-6alkenyloxy, aryloxy, benzyloxy, haloC1-6alkoxy, haloC1-6alkenyloxy, haloaryloxy, nitro, nitroC1-6alkyl, nitroC1-6alkenyl, nitroC1-6alkynyl, nitroaryl, nitroheterocyclyl, amino, C1-6alkylamino, C1-6dialkylamino, C1-6alkenylamino, C1-6alkynylamino, arylamino, diarylamino, benzylamino, dibenzylamino, acyl, C1-6alkenylacyl, C1-6alkynylacyl, arylacyl, acylamino, diacylamino, acyloxy, alkylsulphonyloxy, arylsulphenyloxy, heterocyclyl, heterocycloxy, heterocyclamino, haloheterocyclyl, alkylsulphenyl, arylsulphenyl, carboalkoxy, carboaryloxy, mercapto, benzylthio, acylthio, and phosphorus-containing groups.
- The complex alcohol is mixed with P4O10. In some embodiments, the P4O10 may be partly hydrated (or a polyphosphoric acid).
- The molar ratio of hydroxyl group (of the complex alcohol) to phosphorus may be within a range of about 3:1 to about 1:3. In some embodiments, the molar ratio is within the range of about 2:1 to about 1:2. In one embodiment, the molar ratio is about 2:1.
- In another embodiment, the molar ratio is about 1:1, or substantially equimolar. In this particular embodiment, the molar ratio of hydroxyl group (of the complex alcohol) to P4O10 would be about 1:0.25.
- The process is for phosphorylating a complex alcohol, comprising the steps of:
- (a) mixing the complex alcohol and P4O10 until its exothermic reaction temperature is achieved;
- (b) allowing the reaction mixture of step (a) to react until the exothermic reaction is complete;
- (c) heating or cooling the reaction mixture of step (b) to at least 80° C.; and
- (d) hydrolysing the reaction mixture of step (c).
- This step involves mixing the complex alcohol and P4O10 until its exothermic reaction temperature is achieved.
- The meaning of “exothermic reaction” is well known in the relevant art. It describes a chemical reaction that releases energy by light or, as in the present invention, heat. The term “exothermic reaction temperature” is used herein to refer to the temperature at which the chemical reaction between the complex alcohol and P4O10 commences to release heat. The complex alcohol and P4O10 are mixed until its exothermic reaction temperature is achieved, and may be mixed to form an intimate mixture. Mixing may be achieved by any available means, including stirring (manual or mechanical). In some embodiments, mixing may also involve the use a high-shear mixer.
- In some embodiments, this step may also involve heating the complex alcohol and P4O10 to advance the chemical reaction between the complex alcohol and P4O10to its exothermic reaction temperature. For example, the complex alcohol and P4O10 may be heated so that its exothermic reaction temperature is achieved in a shorter period of time. For example, the complex alcohol and P4O10 may be heated to advance the chemical reaction between the complex alcohol and P4O10to its exothermic reaction temperature in about 15 to 30 minutes.
- In other embodiments, no heating is applied so that the chemical reaction between the complex alcohol and P4O10 achieves its exothermic reaction temperature over the time needed to reach this temperature.
- This step involves allowing the reaction mixture of step (a) to react until the exothermic reaction is complete. In some embodiments, as the reaction progresses, heat is generated by the exothermic reaction process and the temperature of the reaction rises without external heating.
- The exothermic reaction is complete when the temperature of the chemical reaction between the complex alcohol and P4O10 begins to fall.
- In some embodiments, this step does not involve mixing. In alternate embodiments, this step involves mixing. As mentioned above, mixing may be achieved by any available means, including stirring (manual or mechanical), and may also involve the use of a high-shear mixer.
- This step involves heating or cooling the reaction mixture of step (b) to at least 80° C.
- In this step, the temperature is at least 80° C. The term “at least 80° C.” is used herein to refer to a temperature equal to or greater than 80° C. In some embodiments, the temperature is within the range of at least 80° C. to about 160° C. In other embodiments, the temperature is within the range of about 90° C. to 140° C. In one embodiment, the temperature is about 90° C. In another embodiment, the temperature is about 100° C. In yet another embodiment, the temperature is about 110° C.
- The reaction mixture of step (b) will be cooled to the relevant temperature if the temperature of the reaction mixture of step (b) is higher than this temperature after the exothermic reaction between the complex alcohol and P4O10 is complete. In the alternative, the reaction mixture of step (b) will be heated to the relevant temperature if the temperature of the reaction mixture of step (b) is lower than this temperature after the exothermic reaction between the complex alcohol and P4O10 is complete.
- In some embodiments, the heating or cooling of the reaction mixture of step (b) may be allowed to proceed gradually over time. In other embodiments, the time may be limited to a specific period of time. For example, the period of time may be limited to about 30 to about 90 minutes, after which external means is used to further heat or to further cool the reaction mixture of step (b).
- Once at the heated or cooled temperature, the reaction mixture of step (b) may be maintained at this temperature for about 30 to about 180 minutes. In some embodiments, the reaction mixture of step (b) is maintained at this temperature for about 60 to about 180 minutes. In one embodiment, the reaction mixture of step (b) is maintained at this temperature for about 60 to about 120 minutes. In another embodiment, the reaction mixture of step (b) is maintained at this temperature for about 60 minutes.
- This step involves hydrolysing the reaction mixture of step (c).
- Hydrolysis involves the addition of an aqueous solution. The aqueous solution may be water (e.g. deionised water). In some embodiments, an excess amount of water is added during the step of hydrolysis. During hydrolysis, the reaction mixture of step (c) may be maintained at the hydrolysis temperature of at least 80° C. The term “at least 80° C.” has the meaning mentioned above. In some embodiments, the hydrolysis temperature is within the range of at least 80° C. to about 150° C. In some embodiments, the hydrolysis temperature is within the range of about 85° C. to 120° C. In one embodiment, the hydrolysis temperature is within the range of about 90° C. to 110° C. In another embodiment, the hydrolysis temperature is within the range of about 90° C. to 100° C. In yet another embodiment, the hydrolysis temperature is within the range of about 100° C. to 110° C.
- Hydrolysis may be conducted for about 30 to about 180 minutes. In some embodiments, hydrolysis is conducted for about 30 to about 120 minutes. In one embodiment, hydrolysis is conducted for about 60 to about 120 minutes. In another embodiment, hydrolysis is conducted for about 90 to about 120 minutes. In one embodiment, hydrolysis is conducted for about 60 to about 90 minutes.
- The process may be conducted in the absence of an additional solvent. The term “additional solvent” is used herein to refer to a solvent other than the aqueous solution, such as water, used during the step of hydrolysis. In some embodiments, the reaction is conducted without an additional solvent such that the complex alcohol and P4O10 are mixed in neat form.
- The invention also relates to a product obtained by the process. The product obtained by the process may be a phosphorylated mono-complex alcohol, a phosphorylated di-complex alcohol, or a mixture thereof. In particular embodiments, the product is a mixture of a phosphorylated mono-complex alcohol and a phosphorylated di-complex alcohol. In these embodiments, the molar ratio of the mixture of the phosphorylated mono-complex alcohol and the phosphorylated di-complex alcohol may be at least about 2:1, about 2:1, about 6:4 or about 8:2, or within a range of about 4:1 to about 1:4 or about 6:4 to about 8:2.
- In some embodiments, the product obtained by the process may be a cross-coupled phosphate diester.
- It should be appreciated that the product obtained by the process may also comprise residual amounts of unreacted complex alcohol and/or related substances. In such embodiments, the process may further involve purification steps.
- The product obtained by the process may also be further reacted with an amphoteric surfactant.
- In these embodiments, the complex alcohol is a tocopherol, and the phosphorylated complex alcohol is a tocopheryl phosphate. The tocopheryl phosphate may be a mono-tocopheryl phosphate, a di-tocopheryl phosphate, or a mixture thereof.
- In one embodiment, the amphoteric surfactant is a tertiary amine of the formula NR1R2R3, wherein R1 is selected from the group consisting of C6-22 alkyl, and R2 and R3 are independently selected from the group consisting of H, (CH2)nCOOX, (CH2)nCHOHCH2SO3X, (CH2)nCHOHCH2OPO3X, in which X is H or forms a salt with a cation selected from the group consisting of sodium, potassium, lithium, calcium, magnesium, ammonium, alkylammonium and alkanolamine, and n is 1 or 2.
- The term “C6-22 alkyl” refers to a straight or branched chain or cyclic hydrocarbon group having from 6 to 22 carbon atoms. Examples include, but are not limited to, hexyl, cyclohexyl, decyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl and octadecyl.
- In some embodiments, R1 is a C12 alkyl (dodecyl), and R2 and R3 are independently selected from CH2CH2COOH and CH2CH2COONa.
- In particular embodiments, the tertiary amine is 3-[2-carboxyethyl(dodecyl)amino] propanoic acid. In other embodiments, the tertiary amine is 3,3′-dodecylimino)dipropionic acid monosodium salt (or lauryliminodipropionic acid, sodium lauryliminodipropionate or N-lauryl iminodipropionate).
- The product obtained by this further process may be lauryliminodipropionic acid tocopheryl phosphates or a salt thereof. In some embodiments, the salt is a sodium salt.
- Various embodiments/aspects of the present invention will now be described with reference to the following non-limiting examples.
- Synthetic α-tocopherol and P4O10 were mixed (mass ratio 0.170), and with heating, the exothermic reaction temperature was reached within about 15 minutes. Heating was continued until the reaction mixture a temperature of about 120° C. was achieved and then stopped. The temperature of the reaction mixture continued to rise for a brief period of time. When the exothermic reaction was complete, the reaction mixture was allowed to cool without any external control for about 60 minutes. The reaction was then further cooled to a temperature of about 90° C. before hydrolysis was conducted with deionised water for about 60 minutes.
- The process produced about 58.52% w/w mono-tocopheryl phosphate and about 30.49% w/w di-tocopheryl phosphate.
- It was also noted that there was about 0.21% w/w unreacted synthetic α-tocopherol.
- Synthetic α-tocopherol and P4O10 were mixed (mass ratio 0.170), and with heating, the exothermic reaction temperature was reached within about 15 minutes. Heating was continued until the reaction mixture a temperature of about 120° C. was achieved and then stopped. The temperature of the reaction mixture continued to rise for a brief period of time.
- When the exothermic reaction was complete, the reaction mixture was allowed to cool without any external control for about 60 minutes. The reaction was then further cooled to a temperature of about 90° C. before hydrolysis with deionised water was conducted for about 60 minutes.
- The process produced about 59.26% w/w mono-tocopheryl phosphate and about 30.91% w/w di-tocopheryl phosphate.
- It was also noted that there was about 0.20% w/w unreacted synthetic α-tocopherol.
- Natural α-tocopherol (0.07% w/w) and P4O10 were mixed (mass ratio 0.170), and with heating, the exothermic reaction temperature was reached within about 15 minutes. Heating was continued until the reaction mixture a temperature of about 120° C. was achieved and then stopped. The temperature of the reaction mixture continued to rise for a brief period of time. When the exothermic reaction was complete, the reaction mixture was allowed to cool without any external control for about 60 minutes. The reaction was then further cooled to a temperature of about 90° C. before hydrolysis with deionised water was conducted for about 60 minutes.
- The process produced about 55.79% w/w mono-tocopheryl phosphate and about 27.68% w/w di-tocopheryl phosphate.
- It was also noted that there was about 0.07% w/w unreacted synthetic α-tocopherol.
- Propofol (1.07 g, 6.00 mmol) and P4O10 (0.430 g, 1.51 mmol) were combined in a reaction tube and stirred vigorously. The reaction mixture was heated with a H2O bath (50-90° C.) for over 120 minutes so that the exothermic reaction was complete and then hydrolysed with H2O (0.260 g) at 90° C. for 60 minutes.
- After cooling to room temperature the reaction mixture was dissolved in EtOH (30 mL), transferred to a 100 mL RBF and concentrated in vacuo (60° C. H2O bath). The residual red oily solid was suspended in hot hexane (90 mL) and filtered hot. The hexane filtrate was concentrated in vacuo (60° C. H2O bath) to ˜25 mL and then cooled on an ice bath for about 120 minutes. The cold suspension was filtered in vacuo and the filter cake was washed with cold hexane (3×15 mL) and dried in a vacuum oven (55° C.) to give a white powder.
- Mass spectrometry analysis of the end product indicated the formation of the desired monophosphate derivative of propofol.
- Propofol (0.565 g, 3.17 mmol), D-α-Tocopherol (1.35 g, 3.13 mmol) and P4O10 (0.462 g, 1.63 mmol) were combined in a Radleys 12 Station Carousel reaction tube. The reaction mixture was heated at 100° C. for 120 minutes to allow the respective exothermic reactions to complete. The reaction mixture was then cooled to 90° C. before hydrolysis with H2O (0.360 g) at that temperature for 60 minutes.
- After cooling to room temperature, the reaction mixture was diluted with EtOH (30 mL), filtered and concentrated in vacuo (60° C. H2O bath) to give a brown oil substance.
- Mass spectrometry analysis of the end product indicated the formation of the monophosphate derivatives of propofol and D-α-tocopherol, as well as the cross-coupled phosphate diester.
- Lauryl alcohol (0.990 g, 5.31 mmol) and P4O10 (0.530 g, 1.87 mmol) were combined in a Radleys 12 Station Carousel reaction tube and stirred vigorously. The reaction mixture was heated at 100° C. for 60 minutes and the exothermic reaction to complete. The reaction mixture was then cooled to 90° C. before hydrolysis with H2O (0.140 g) at that temperature for 60 minutes.
- After cooling to room temperature, the reaction mixture was partitioned between Et2O (6 mL) and H2O (6 mL). The Et2O phase was concentrated in vacuo (60° C. H2O bath) to give a yellow liquid.
- Mass spectrometry analysis of the end product indicated the formation of the desired monophosphate derivative of lauryl alcohol.
- β-Estradiol (0.490 g, 1.80 mmol) and P4O10 (0.140 g, 0.493 mmol) were combined in a Radleys 12 Station Carousel reaction tube and suspended in Triacetin (2 mL). The reaction mixture was heated at 100° C. for 60 minutes and to complete the exothermic reaction. The reaction mixture was then cooled to 90° C. before it was hydrolysed with H2O (1.00 g) at that temperature for 60 minutes.
- After cooling to room temperature, the reaction mixture was washed with hexane (2×25 mL). The resultant suspension was dissolved in THF (30 mL) and concentrated in vacuo (60° C. H2O bath) to give an oily beige solid. Mass spectrometry analysis of the end product indicated the formation of the desired monophosphate derivative.
- In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word “comprise” or variations such as “comprises” or “comprising” is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.
Claims (14)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2016905298A AU2016905298A0 (en) | 2016-12-21 | Process | |
AU2016905298 | 2016-12-21 | ||
PCT/AU2017/051381 WO2018112512A1 (en) | 2016-12-21 | 2017-12-13 | Process |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2017/051381 A-371-Of-International WO2018112512A1 (en) | 2016-12-21 | 2017-12-13 | Process |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/552,188 Continuation US11753435B2 (en) | 2016-12-21 | 2021-12-15 | Process |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190330260A1 true US20190330260A1 (en) | 2019-10-31 |
Family
ID=62624385
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/470,943 Abandoned US20190330260A1 (en) | 2016-12-21 | 2017-12-13 | Process |
US17/552,188 Active US11753435B2 (en) | 2016-12-21 | 2021-12-15 | Process |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/552,188 Active US11753435B2 (en) | 2016-12-21 | 2021-12-15 | Process |
Country Status (11)
Country | Link |
---|---|
US (2) | US20190330260A1 (en) |
EP (1) | EP3558903A4 (en) |
JP (1) | JP7198754B2 (en) |
KR (1) | KR102647670B1 (en) |
CN (1) | CN110662733A (en) |
AU (2) | AU2017381395A1 (en) |
BR (1) | BR112019012946A2 (en) |
CA (1) | CA3045702A1 (en) |
IL (1) | IL267006A (en) |
MX (1) | MX2019006845A (en) |
WO (1) | WO2018112512A1 (en) |
Family Cites Families (301)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2407823A (en) | 1946-09-17 | Antihemorrhagic esters and methods | ||
US2457932A (en) | 1949-01-04 | Salts of tocopheryl phosphoric | ||
US2667479A (en) | 1951-01-30 | 1954-01-26 | Merck & Co Inc | Benzimidazole phosphate |
GB778142A (en) | 1953-11-20 | 1957-07-03 | Leo Ab | High-molecular weight derivatives of hydroxyl group-containing steroids and a method of producing them |
US2913477A (en) | 1957-03-22 | 1959-11-17 | Merck & Co Inc | Antihemorrhagic compounds and processes for preparing the same |
US3127434A (en) | 1959-10-20 | 1964-03-31 | Hoffmann La Roche | Dihydrovitamin k monophosphate compounds and preparation thereof |
US3212901A (en) | 1961-06-07 | 1965-10-19 | Eastman Kodak Co | Stabilized tocopherol concentrates and process for preparing the same |
US3331896A (en) | 1964-09-15 | 1967-07-18 | Gen Aniline & Film Corp | Method of preparing alkali soluble phosphate esters of hydroxylic organic compounds |
US3607765A (en) | 1968-11-29 | 1971-09-21 | Colgate Polmolive Co | Detergent softener compositions |
JPS5022535A (en) | 1973-06-27 | 1975-03-11 | ||
DE2526938C2 (en) | 1975-02-14 | 1982-04-22 | F. Hoffmann-La Roche & Co. AG, 4002 Basel | Vitamin preparations |
JPS521858A (en) | 1975-06-24 | 1977-01-08 | Hitachi Metals Ltd | Steel pipe transfer apparatus |
JPS5239013A (en) | 1975-09-23 | 1977-03-26 | Shintaro Yamada | Forced draft diesel engine |
JPS6035347B2 (en) | 1976-07-26 | 1985-08-14 | エーザイ株式会社 | Synthesis method of α-tocopherol |
US4141938A (en) * | 1976-10-07 | 1979-02-27 | Hoechst Aktiengesellschaft | Production of acid orthophosphoric acid ester mixtures |
US4444755A (en) | 1978-01-23 | 1984-04-24 | Efamol Limited | Treatment for skin disorders |
US4299906A (en) | 1979-06-01 | 1981-11-10 | American Hoechst Corporation | Light-sensitive color proofing film with surfactant in a light-sensitive coating |
SU925961A1 (en) | 1980-08-15 | 1982-05-07 | Московский ордена Трудового Красного Знамени технологический институт пищевой промышленности | Process for producing higher fatty acid phosphorilated glycerides |
US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
IT1157269B (en) | 1982-03-19 | 1987-02-11 | Seuref Ag | NEW PHARMACEUTICAL FORMULATIONS CONTAINING COENZYME Q10 SUITABLE FOR TOPICAL ADMINISTRATION |
JPS58180410A (en) | 1982-04-16 | 1983-10-21 | Shiseido Co Ltd | Cosmetic |
JPS5944375A (en) | 1982-09-06 | 1984-03-12 | Senjiyu Seiyaku Kk | Stable aqueous solution of alpha-tocopherol phosphoric ester |
JPH0247997B2 (en) | 1983-02-25 | 1990-10-23 | Sanyo Chemical Ind Ltd | RINSANESUTERUNOSEIZOHO |
JPS6048962A (en) | 1983-08-26 | 1985-03-16 | Chisso Corp | Preparation of sulfamic acid guanidine |
JPS6056699A (en) | 1983-09-08 | 1985-04-02 | 三菱重工業株式会社 | Half-warm water catamaran |
JPS60197621A (en) | 1984-03-19 | 1985-10-07 | Hohnen Oil Co Ltd | Hypocholesterolemic |
CH661438A5 (en) | 1984-04-09 | 1987-07-31 | Seuref Ag | Pharmaceutical compositions acting antianossica and metabolic brain. |
US4977282A (en) | 1984-04-17 | 1990-12-11 | Henkel Corporation | Production of d-alpha-tocopherol from natural plant sources |
US4603142A (en) | 1984-06-01 | 1986-07-29 | Wisconsin Alumni Research Foundation | Cholesterol lowering method of use |
EP0171009B1 (en) | 1984-08-02 | 1991-05-22 | HENKEL CORPORATION (a Delaware corp.) | Purification of tocopherols by extraction |
JPS6186940A (en) | 1984-10-02 | 1986-05-02 | Kao Corp | Oil in water type emulsion composition |
JPS6191137A (en) | 1984-10-11 | 1986-05-09 | Kao Corp | External drug composition |
JPS61176535A (en) | 1985-01-31 | 1986-08-08 | Morishita Jintan Kk | Enteric drug preparation |
JP2540294B2 (en) | 1985-04-09 | 1996-10-02 | 花王株式会社 | Transdermal formulation |
JPS62195393A (en) | 1986-02-21 | 1987-08-28 | Yakult Honsha Co Ltd | Novel camptothecin derivative and production thereof |
JPS6393791A (en) | 1986-10-08 | 1988-04-25 | Nippon Shokubai Kagaku Kogyo Co Ltd | Phosphoric ester and preparation thereof |
JPH0781138B2 (en) | 1986-12-02 | 1995-08-30 | 株式会社資生堂 | Antioxidant |
DE3702766A1 (en) * | 1987-01-30 | 1988-08-11 | Henkel Kgaa | METHOD FOR PRODUCING AND ISOLATING MONOALKYLPHOSPHORIC ACID ESTERS |
JP3070744B2 (en) | 1987-04-10 | 2000-07-31 | 株式会社日立製作所 | Vector processing equipment |
US4952495A (en) | 1987-06-08 | 1990-08-28 | Eastman Kodak Company | Hydrolyzable compounds which release electron transfer agents and analytical use of same |
PH25859A (en) | 1988-01-11 | 1991-12-02 | Takeda Chemical Industries Ltd | Composition for treatment of ischemic disorder |
US5234957A (en) | 1991-02-27 | 1993-08-10 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5446070A (en) | 1991-02-27 | 1995-08-29 | Nover Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
JPH01228920A (en) | 1988-03-09 | 1989-09-12 | Kuraray Co Ltd | Absorbefacient |
DE3813624A1 (en) | 1988-04-22 | 1989-11-02 | Basf Ag | METHOD FOR PRODUCING D- (ALPHA) -TOCOPHEROL FROM NATURAL PRE-PRODUCTS |
JPH01274830A (en) | 1988-04-28 | 1989-11-02 | Asahi Denka Kogyo Kk | Safe lipid composition having high surface activity |
CA2007643A1 (en) | 1989-02-01 | 1990-08-01 | Donald S. Karanewsky | Combination of an hmg coa reductase inhibitor and a squalene synthetase inhibitor and method for lowering serum cholesterol using such combination |
US6028105A (en) | 1989-04-06 | 2000-02-22 | Nigra; Thomas P. | Topical drug delivery composition and method |
JP3040427B2 (en) | 1989-05-18 | 2000-05-15 | 帝國製薬株式会社 | Aspirin-containing ointment composition for treating neuralgia |
US5053222A (en) | 1989-06-07 | 1991-10-01 | Shiseido Company Ltd. | Hair cosmetic composition |
US5094848A (en) | 1989-06-30 | 1992-03-10 | Neorx Corporation | Cleavable diphosphate and amidated diphosphate linkers |
DE3927113C2 (en) | 1989-08-17 | 1993-11-25 | Dolorgiet Gmbh & Co Kg | Agent for the treatment of severe pain conditions and process for their preparation |
JPH03120230A (en) | 1989-10-04 | 1991-05-22 | Nippon Mining Co Ltd | Percutaneous absorbefacient of drug active ingredient and percutaneous absorption type pharmaceutical |
JP2854631B2 (en) | 1989-11-21 | 1999-02-03 | 千寿製薬株式会社 | Prevention and treatment of diabetic complications and diseases caused by aging |
IT1236843B (en) | 1989-11-22 | 1993-04-21 | Simes | PROCESS FOR THE PREPARATION OF 4-0-DOPAMINE PHOSPHATES OR ITS DERIVATIVES |
JPH03206089A (en) | 1990-01-05 | 1991-09-09 | Eisai Co Ltd | New vitamin e derivative and production thereof |
US5374645A (en) | 1990-01-22 | 1994-12-20 | Ciba-Geigy Corporation | Transdermal administation of ionic pharmaceutically active agents via aqueous isopropanol |
FR2657526B1 (en) | 1990-01-31 | 1994-10-28 | Lvmh Rech | USE OF AN ALPHA-TOCOPHEROL PHOSPHATE, OR ONE OF ITS DERIVATIVES, FOR THE PREPARATION OF COSMETIC, DERMATOLOGICAL, OR PHARMACEUTICAL COMPOSITIONS; COMPOSITIONS THUS OBTAINED. |
US5041434A (en) | 1991-08-17 | 1991-08-20 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
US5114957A (en) | 1990-05-08 | 1992-05-19 | Biodor U.S. Holding | Tocopherol-based antiviral agents and method of using same |
CA2081982A1 (en) | 1990-05-21 | 1991-11-22 | Kenneth John Murray | Phenol and pyridinol derivatives as pharmaceuticals |
CA2067754C (en) | 1990-08-24 | 2002-06-04 | Gregor Cevc | Preparation for the application of agents in mini-droplets |
WO1992007544A1 (en) | 1990-10-26 | 1992-05-14 | Shiseido Co., Ltd. | External preparation for skin |
SE9003665D0 (en) | 1990-11-16 | 1990-11-16 | Kabivitrum Ab | MORPHINE PRODRUGS |
JP3035742B2 (en) | 1990-11-30 | 2000-04-24 | 昭和電工株式会社 | Cosmetics |
JP2983311B2 (en) | 1991-02-26 | 1999-11-29 | 株式会社資生堂 | External preparation for skin |
US5646190A (en) | 1991-03-01 | 1997-07-08 | Warner-Lambert Company | Acne treating-wound healing compositions and methods for preparing and using same |
JPH05946A (en) | 1991-06-27 | 1993-01-08 | Nichiban Co Ltd | Ketotifen-containing percutaneous absorption preparation |
US5643597A (en) | 1991-08-01 | 1997-07-01 | Lvmh Recherche | Use of a tocopherol phosphate or one of its derivatives for the preparation of cosmetic or pharmaceutical compositions and compositions so obtained |
FR2679904A1 (en) | 1991-08-01 | 1993-02-05 | Lvmh Rech | Use of a tocopherol phosphate, or of one of its derivatives, in the preparation of cosmetic or pharmaceutical compositions and compositions thus obtained |
EP0535283A1 (en) | 1991-10-02 | 1993-04-07 | Merrell Dow Pharmaceuticals Inc. | Cardioprotective tocopherol analogs |
US5474891A (en) | 1991-10-30 | 1995-12-12 | Thomas Jefferson University | Plasma-based platelet concentrate preparations with additive |
EP0612521B1 (en) | 1991-11-11 | 1999-06-30 | Hisamitsu Pharmaceutical Co., Inc. | Fomentation containing ketorolac |
EP0543417A1 (en) | 1991-11-22 | 1993-05-26 | Lipogenics, Incorporated | Tocotrienols and tocotrienol-like compounds and methods for their use |
US5282312A (en) | 1991-12-31 | 1994-02-01 | Tessera, Inc. | Multi-layer circuit construction methods with customization features |
AU3662093A (en) | 1992-02-14 | 1993-09-03 | Robert Lamb | Phosphate derivatives of vitamin e to protect cells from effects of aging and injury |
JP3207494B2 (en) | 1992-04-02 | 2001-09-10 | ロート製薬株式会社 | Aqueous suspension formulation |
JPH05286848A (en) | 1992-04-10 | 1993-11-02 | Senju Pharmaceut Co Ltd | Bathing agent |
US5731299A (en) | 1992-05-29 | 1998-03-24 | The Procter & Gamble Company | Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
GB9212450D0 (en) | 1992-06-11 | 1992-07-22 | Indena Spa | New derivatives of non-steroidal anti-inflammatory,analgesic and/or antipyretic substances,their use and pharmaceutical formulations containing them |
US5741518A (en) | 1992-08-03 | 1998-04-21 | L'oreal | Composition composed of an aqueous dispersion of stabilized vesicles of nonionic amphiphilic lipids |
US5773457A (en) | 1995-02-15 | 1998-06-30 | Cesar Roberto Dias Nahoum | Compositions |
WO1994008599A1 (en) | 1992-10-14 | 1994-04-28 | The Regents Of The University Of Colorado | Ion-pairing of drugs for improved efficacy and delivery |
US6384043B1 (en) | 1993-02-01 | 2002-05-07 | Gholam A. Peyman | Methods of alleviating pain sensations of the denuded eye with opioid analgesics |
TW252918B (en) | 1993-03-31 | 1995-08-01 | Senju Pharma Co | |
DE4336557C2 (en) | 1993-05-06 | 1997-07-17 | Lohmann Therapie Syst Lts | Estradiol-containing transdermal therapeutic system, process for its preparation and its use |
JP3179629B2 (en) | 1993-06-24 | 2001-06-25 | 花王株式会社 | Liquid detergent composition |
CN1077800C (en) | 1993-07-01 | 2002-01-16 | 韩美药品工业株式会社 | Cyclosporin soft capsule composition |
GB9318271D0 (en) | 1993-09-03 | 1993-10-20 | Scotia Holdings Plc | Tocopherols |
CA2129509A1 (en) | 1993-09-10 | 1995-03-11 | Kazumi Ogata | Pharmaceutical composition for renal disorder and a dialysis solution for extracorporeal hemodialysis |
WO1995014457A1 (en) | 1993-11-27 | 1995-06-01 | Knoll Ag | Compositions comprising iminium ion scavengers and/or nitrite scavengers |
JPH07196516A (en) | 1993-12-29 | 1995-08-01 | Senju Pharmaceut Co Ltd | Therapeutic agent for hemorrhoids |
FR2714595B1 (en) | 1993-12-30 | 1996-02-02 | Oreal | Water in oil emulsion containing retinol, its use and packaging. |
JPH07207298A (en) | 1994-01-21 | 1995-08-08 | Nippon Oil & Fats Co Ltd | Detergent composition |
FR2715565B1 (en) | 1994-01-31 | 1996-03-15 | Oreal | Stabilized cosmetic or dermatological composition containing several precursors of the same active ingredient to maximize its release, its use. |
EP0669132A1 (en) | 1994-02-23 | 1995-08-30 | van der Kraaij, Antonius Marinus Maria | Pharmaceutical composition of vitamin E and acetylsalicylate for treatment and prevention of atherosclerosis |
CA2145229A1 (en) | 1994-03-29 | 1995-09-30 | Tetsuya Toge | Suppressory compositions against hepatic metastases of tumors |
US5554781A (en) * | 1994-03-30 | 1996-09-10 | Reierson; Robert L. | Monoalkyl phosphonic acid ester production process |
EP1207135B1 (en) * | 1994-03-30 | 2008-03-05 | Rhodia Inc. | Phosphation reagent, process and use |
JPH07277988A (en) | 1994-04-05 | 1995-10-24 | Senju Pharmaceut Co Ltd | Locally itch-removing and treating agent |
JPH07278587A (en) | 1994-04-06 | 1995-10-24 | Kao Corp | Detergent composition |
TW287103B (en) | 1994-04-22 | 1996-10-01 | Senju Pharma Co | |
JP3362501B2 (en) | 1994-04-28 | 2003-01-07 | 千寿製薬株式会社 | Corneal disorder treatment |
JP3396953B2 (en) | 1994-05-10 | 2003-04-14 | 千寿製薬株式会社 | Retinal disease prevention / treatment agent |
GB9409778D0 (en) | 1994-05-16 | 1994-07-06 | Dumex Ltd As | Compositions |
JPH07316170A (en) | 1994-05-24 | 1995-12-05 | Kao Corp | Production of phosphoric monoester |
AU2825295A (en) | 1994-06-13 | 1996-01-05 | Arcturus Pharmaceutical Corporation | Method for the treatment, prevention or minimization of hair loss |
US5589504A (en) | 1994-07-26 | 1996-12-31 | Cornell Research Foundation, Inc. | Treatment of newborn jaundice |
CA2152693A1 (en) | 1994-08-05 | 1996-02-06 | Kazumi Ogata | Therapeutic composition for pancreatitis |
IT1274734B (en) | 1994-08-25 | 1997-07-24 | Prospa Bv | PHARMACEUTICAL COMPOSITIONS CONTAINING POLYUNSATURATED FATTY ACIDS, THEIR ESTERS OR SALTS, WITH VITAMINS OR ANTIOXIDANT PROVITAMINS |
JPH0873338A (en) | 1994-09-02 | 1996-03-19 | Noevir Co Ltd | Skin external preparation |
HU215966B (en) | 1994-11-21 | 1999-07-28 | BIOGAL Gyógyszergyár Rt. | Oral multiple emulsion-preconcentrate containing cyclosporin |
KR100261858B1 (en) * | 1994-12-09 | 2000-07-15 | 고토다쿠야 | Process for the preparation of phosphoric monoester |
JP3558757B2 (en) * | 1994-12-09 | 2004-08-25 | 花王株式会社 | Method for producing phosphate ester |
DE4444238A1 (en) | 1994-12-13 | 1996-06-20 | Beiersdorf Ag | Cosmetic or dermatological drug combinations of cinnamic acid derivatives and flavone glycosides |
SE9404568L (en) | 1994-12-30 | 1996-07-01 | Perstorp Ab | Use of inositol trisphosphate for drug preparation |
AU4515996A (en) | 1995-01-09 | 1996-07-31 | Alpha-Therapeutics, Inc. | Methods for increasing the bioavailability of biological active agents |
JP3526940B2 (en) | 1995-01-11 | 2004-05-17 | 花王株式会社 | Method for producing phosphate ester |
FR2730928B1 (en) | 1995-02-23 | 1997-04-04 | Oreal | COMPOSITION BASED ON LIPIDIC VESICLES WITH ACIDIC PH AND USE THEREOF IN TOPICAL APPLICATION |
JPH08231564A (en) | 1995-02-28 | 1996-09-10 | Nippon Shokubai Co Ltd | Phosphoric acid ester, its production and phosphoric acid ester polymer |
GB9505025D0 (en) | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
EP0766960B1 (en) | 1995-04-21 | 2003-09-17 | Sekisui Kagaku Kogyo Kabushiki Kaisha | External preparations for treating dermatoses |
JP3197787B2 (en) | 1995-05-17 | 2001-08-13 | 花王株式会社 | Method for producing branched dimerized alkyl phosphate basic amino acid salt |
JPH08311489A (en) | 1995-05-19 | 1996-11-26 | Nippon Oil & Fats Co Ltd | Detergent composition |
US5665389A (en) | 1995-05-24 | 1997-09-09 | University Of Maryland At Baltimore | Oral dosage composition for intestinal delivery and method of treating diabetes |
JP3622267B2 (en) | 1995-05-31 | 2005-02-23 | 日本油脂株式会社 | Cleaning composition |
US5607968A (en) | 1995-06-07 | 1997-03-04 | Avon Products, Inc. | Topical alkyl-2-O-L-ascorbyl-phosphates |
JP3609834B2 (en) | 1995-07-12 | 2005-01-12 | 株式会社 資生堂 | Skin preparation |
JPH0944375A (en) | 1995-07-26 | 1997-02-14 | Hitachi Ltd | Automatic test item selection system for test program |
JP4115524B2 (en) | 1995-10-17 | 2008-07-09 | 昭和電工株式会社 | High-purity tocopherol phosphates, production method thereof, analysis method thereof and cosmetics |
FR2741263B1 (en) | 1995-11-22 | 1997-12-26 | Oreal | COMPOSITION COMPRISING AN AQUEOUS DISPERSION OF LIPID VESICLES ENCAPSULATING AN ACID-FUNCTIONAL UV FILTER AND USES FOR TOPICAL APPLICATION |
CN1229114C (en) | 1996-03-27 | 2005-11-30 | 印斯拜尔药品股份有限公司 | Method of treating ciliary dyskinesia with uridine triphosphates and related compounds |
US6077828A (en) | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
US5885595A (en) | 1996-05-13 | 1999-03-23 | Elizabeth Arden Co., Division Of Conopco, Inc. | Cosmetic composition with a retinol fatty acid ester |
JPH09309813A (en) | 1996-05-22 | 1997-12-02 | Nonogawa Shoji Kk | Preparation for external use for skin |
JPH1045783A (en) | 1996-07-29 | 1998-02-17 | Showa Denko Kk | Production of hydroxychromanic acid derivative phosphoric ester |
CA2209690A1 (en) | 1996-07-31 | 1998-01-31 | Sachiko Matsuura | Therapeutic drug for acne vulgaris |
JPH1067639A (en) | 1996-08-26 | 1998-03-10 | Shiseido Co Ltd | Vitamin e-vitamin c phosphoric diester/cyclodextrin clathrate and external preparation for skin containing the same |
US6022867A (en) | 1996-11-27 | 2000-02-08 | Showa Denko Kabushiki Kaisha | Method of administering vitamin E to animals and compositions containing tocopheryl phosphates and salts thereof for animals |
JPH10155429A (en) | 1996-11-27 | 1998-06-16 | Showa Denko Kk | Method for supplying vitamin e to animals and tocopherol phosphate for animals or its salts composition |
US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
US6727280B2 (en) | 1997-01-07 | 2004-04-27 | Sonus Pharmaceuticals, Inc. | Method for treating colorectal carcinoma using a taxane/tocopherol formulation |
US5804168A (en) | 1997-01-29 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for protecting and treating sun damaged skin |
US6932975B2 (en) | 1997-01-29 | 2005-08-23 | Kao Corporation | Cosmetic composition comprising a phosphoric triester and a skin activating component |
US6248758B1 (en) | 1997-03-13 | 2001-06-19 | Hexal Ag | Pharmaceutical antacid |
US7179486B1 (en) | 1997-04-01 | 2007-02-20 | Nostrum Pharmaceuticals, Inc. | Process for preparing sustained release tablets |
FR2764891B1 (en) | 1997-06-04 | 2001-04-13 | Pacific Corp | DERIVED FROM L-ASCORBIC ACID STABLE IN WATER, PROCESS FOR ITS PREPARATION AND COSMETIC COMPOSITION OF BLEACHING THE SKIN CONTAINING IT |
US5928631A (en) | 1997-06-09 | 1999-07-27 | The Procter & Gamble Company | Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins |
US5906811A (en) | 1997-06-27 | 1999-05-25 | Thione International, Inc. | Intra-oral antioxidant preparations |
JPH1143436A (en) | 1997-07-25 | 1999-02-16 | Showa Denko Kk | Medicine for preventing/treating periphery blood stream disorder |
US5776915A (en) | 1997-08-12 | 1998-07-07 | Clarion Pharmaceuticals Inc. | Phosphocholines of retinoids |
US6096326A (en) | 1997-08-15 | 2000-08-01 | Scandinavian-American Import/Export Corporation | Skin care compositions and use |
IT1294748B1 (en) | 1997-09-17 | 1999-04-12 | Permatec Tech Ag | FORMULATION FOR A TRANSDERMAL DEVICE |
JP3950216B2 (en) | 1997-12-26 | 2007-07-25 | 日本メナード化粧品株式会社 | Topical skin preparation |
WO1999033846A2 (en) | 1997-12-31 | 1999-07-08 | The University Of Kansas | Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof |
JPH11199465A (en) | 1998-01-07 | 1999-07-27 | Nonogawa Shoji Kk | Skin preparation for external use |
AU2113199A (en) | 1998-01-12 | 1999-07-26 | Betagene, Inc. | Media for neuroendocrine cells |
EP1053749A4 (en) | 1998-02-03 | 2003-01-15 | Senju Pharma Co | Preventives and remedies for neuron digeneration-associated diseaseas |
FR2777179A1 (en) | 1998-04-09 | 1999-10-15 | Lvmh Rech | Cosmetic and dermatological composition with non-greasy feel and useful as carrier |
US6461623B2 (en) | 1998-04-13 | 2002-10-08 | Kao Corporation | Cosmetic composition |
US6254853B1 (en) | 1998-05-08 | 2001-07-03 | Vyrex Corporation | Water soluble pro-drugs of propofol |
US6121249A (en) | 1998-07-01 | 2000-09-19 | Donald L. Weissman | Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins |
ATE399565T1 (en) | 1998-07-07 | 2008-07-15 | Transdermal Technologies Inc | COMPOSITIONS FOR THE RAPID AND NON-IRRITATIVE TRANSDERMAL ADMINISTRATION OF PHARMACEUTICALS AND METHODS OF FORMULATION AND ADMINISTRATION THEREOF |
US6204257B1 (en) | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
US6703384B2 (en) | 1998-09-23 | 2004-03-09 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
US6770672B1 (en) | 1998-09-23 | 2004-08-03 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
IL142082A (en) | 1998-09-23 | 2005-12-18 | Res Dev | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
US6153582A (en) | 1998-11-05 | 2000-11-28 | Bausch & Lomb Surgical, Inc. | Defined serumfree medical solution for ophthalmology |
IT1303787B1 (en) | 1998-11-25 | 2001-02-23 | Maria Rosa Gasco | "SOLID LIPID NANOSPHERES SUITABLE FOR FAST INTERNALIZATION IN THE CELLS" |
US6048891A (en) | 1998-12-17 | 2000-04-11 | Loma Linda University Medical Center | Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease |
AU766255B2 (en) | 1999-01-25 | 2003-10-09 | Vital Health Sciences Pty Ltd | Improved process for phosphorylation and compounds produced by this process |
AUPP829399A0 (en) | 1999-01-25 | 1999-02-18 | Swig Pty Ltd | Recovery for chroman derivatives |
AUPQ037499A0 (en) * | 1999-05-14 | 1999-06-10 | Swig Pty Ltd | Improved process for phosphorylation and compounds produced by this method |
JP2000212082A (en) | 1999-01-26 | 2000-08-02 | Showa Denko Kk | Preparation for external use for skin |
NZ527924A (en) | 1999-01-29 | 2005-01-28 | Mars Uk Ltd | Antioxidant compositions and methods for companion animals |
US6156354A (en) | 1999-01-29 | 2000-12-05 | Brandeis University | Hyper-absorption of vitamin E dispersed in milks |
GB9903547D0 (en) | 1999-02-16 | 1999-04-07 | Novartis Ag | Organic compounds |
DE19912798C1 (en) | 1999-03-10 | 2000-02-17 | Andreas Jordan | Culturing human cancer cells for molecular biology research comprises culturing fragments of tissue slices |
AU3913800A (en) | 1999-03-26 | 2000-10-16 | Lipogenics, Inc. | Novel antioxidant formulations and methods for using them |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
CA2372066C (en) * | 1999-05-14 | 2006-01-31 | Simon Michael West | Process for phosphorylation of primary fatty alcohols,secondary alcohols and aromatic alcohols using p4o10 in the absence of solvent |
DE19923551A1 (en) | 1999-05-21 | 2000-11-30 | Lohmann Therapie Syst Lts | Pharmaceutical preparation with the active ingredient diamorphine and its use in a method for treating opiate addiction |
US6184247B1 (en) | 1999-05-21 | 2001-02-06 | Amway Corporation | Method of increasing cell renewal rate |
AU5594700A (en) | 1999-06-01 | 2000-12-18 | Ocean Spray Cranberries, Inc. | Cranberry seed oil extract and compositions containing components thereof |
EP1187618A1 (en) | 1999-06-04 | 2002-03-20 | The General Hospital Corporation | Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use |
NZ517833A (en) | 1999-08-20 | 2004-01-30 | Ferrosan As | Oral delivery of antioxidants vitamin C and vitamin E combinations in slow- and plain-release formulations for treating oxidative stress |
US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
US6423742B1 (en) | 1999-09-02 | 2002-07-23 | Drake Larson | Compositions for reducing vascular plaque formation and methods of using same |
GB9921960D0 (en) | 1999-09-16 | 1999-11-17 | Pharmacia & Upjohn Spa | Formulations for parenteral use of estramustine phosphate and amino acids |
KR20020059415A (en) | 1999-09-27 | 2002-07-12 | 스티븐 씨. 큐웨이 | Compositions of tocol-soluble therapeutics |
WO2001035998A1 (en) | 1999-11-12 | 2001-05-25 | Pharmaderm Laboratories, Ltd. | Compositions for transdermal and transmucosal administration of therapeutic agents |
AU1780101A (en) | 1999-11-19 | 2001-05-30 | Xel Herbaceuticals | Transdermal delivery system for alkaloids of aconitum species |
JP2001169731A (en) | 1999-12-17 | 2001-06-26 | Showa Denko Kk | Lipid metabolism improving agent for animal |
WO2001046204A1 (en) | 1999-12-22 | 2001-06-28 | Merck Frosst Canada & Co. | Aromatic phosphonates as protein tyrosine phosphatase 1b (ptp-1b) inhibitors |
IT1317736B1 (en) | 2000-01-26 | 2003-07-15 | A C R Applied Coating Res S A | PATCH FOR LOCAL AND TRANSDERMAL ADMINISTRATION OF PRINCIPIACTIVES EQUIPPED WITH ANIONIC GROUPS AND ELECTRONATTRACTORS. |
KR100847678B1 (en) | 2000-02-11 | 2008-07-23 | 리서치 디벨럽먼트 파운데이션 | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
US6635253B2 (en) | 2000-02-29 | 2003-10-21 | Showa Denko Kabushiki Kaisha | Composition for enhancing immunological effects |
US6346544B2 (en) | 2000-03-02 | 2002-02-12 | Oklahoma Medical Research Foundation | Desmethyl tocopherols for protecting cardiovascular tissue |
JP2001247585A (en) | 2000-03-03 | 2001-09-11 | Nof Corp | Tocopherol derivative, intermediate for the same, method of producing the same, and application for the same |
US6444220B2 (en) | 2000-03-16 | 2002-09-03 | Teresa S. Wiley | Method and compositions for changing the contour of skin |
AU2001247726A1 (en) | 2000-03-24 | 2001-10-08 | Baker Norton Pharmaceuticals, Inc. | Taxane-based compositions and methods of use |
US6361800B1 (en) | 2000-04-13 | 2002-03-26 | Cooper Concepts, Inc. | Multi-vitamin and mineral supplement |
DE10032301A1 (en) | 2000-07-04 | 2002-01-17 | Rbs Netkom Gmbh | Driving data acquisition, transmission and output system |
FR2811546B1 (en) | 2000-07-13 | 2003-09-26 | Oreal | LONG-LASTING MAKEUP KIT AND METHOD |
US6485950B1 (en) | 2000-07-14 | 2002-11-26 | Council Of Scientific And Industrial Research | Isozyme of autoclavable superoxide dismutase (SOD), a process for the identification and extraction of the SOD in cosmetic, food and pharmaceutical compositions |
US6362234B1 (en) | 2000-08-15 | 2002-03-26 | Vyrex Corporation | Water-soluble prodrugs of propofol for treatment of migrane |
KR100365070B1 (en) | 2000-08-29 | 2002-12-16 | 주식회사 태평양 | Tocopherol derivatives and method for preparation thereof |
JP4818500B2 (en) | 2000-09-05 | 2011-11-16 | 株式会社ペンタプラストア | Tocotrienol derivative and method for producing the same |
WO2002026238A1 (en) | 2000-09-26 | 2002-04-04 | Vital Health Sciences Pty Ltd. | Phosphate derivative supplements |
US6660306B2 (en) | 2000-10-12 | 2003-12-09 | Mickey L. Peshoff | Wound healing compound |
US20030206972A1 (en) | 2000-10-13 | 2003-11-06 | Babish John G. | Compositions containing carotenoids and tocotrienols and having synergistic antioxidant effect |
AU2002220021A1 (en) | 2000-11-02 | 2002-05-15 | The Regents Of The University Of California | Alpha-tocopherol transfer protein knockout animals |
AU2002214820B2 (en) | 2000-11-14 | 2003-08-14 | Vital Health Sciences Pty Ltd | Formulation containing phosphate derivatives of electron transfer agents |
CN1262274C (en) | 2000-11-14 | 2006-07-05 | 生命健康科学有限公司 | Complexes of phosphate derivatives |
AUPR549901A0 (en) | 2001-06-06 | 2001-07-12 | Vital Health Sciences Pty Ltd | Topical formulation containing tocopheryl phosphates |
AU2002228648A1 (en) | 2000-11-16 | 2002-05-27 | Pharmacia And Upjohn Company | Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists |
IN188917B (en) | 2000-12-07 | 2002-11-23 | Bharat Surums & Vaccines Ltd | |
WO2002047680A2 (en) | 2000-12-15 | 2002-06-20 | Galileo Laboratories, Inc. | Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia |
US20020151467A1 (en) | 2000-12-21 | 2002-10-17 | Leung Frank K. | Methods and compositions for oral insulin delivery |
US20020131994A1 (en) | 2001-01-10 | 2002-09-19 | Schur Henry B. | Non-irritating formulation for the transdermal delivery of substances |
US6849271B2 (en) | 2001-04-27 | 2005-02-01 | Verion, Inc. | Microcapsule matrix microspheres, absorption-enhancing pharmaceutical compositions and methods |
TW576859B (en) | 2001-05-11 | 2004-02-21 | Shipley Co Llc | Antireflective coating compositions |
KR100428702B1 (en) | 2001-05-26 | 2004-04-28 | 주식회사 엘지생명과학 | Feed additive compositions for animals comprising polyethoxylated alpha tocopherol ester derivatives |
KR100394770B1 (en) | 2001-06-05 | 2003-08-14 | 주식회사 태평양 | Stabilization method of nano-emulsion using tocopheryl derivatives and external application for skin containing the stabilized nano-emulsion |
BR0211673A (en) | 2001-07-27 | 2004-07-13 | Vital Health Sciences Pty Ltd | Dermal therapy using phosphate derivatives of electron transfer agents |
AUPR684801A0 (en) | 2001-08-06 | 2001-08-30 | Vital Health Sciences Pty Ltd | Supplement therapy |
RU2302857C2 (en) | 2001-09-04 | 2007-07-20 | Тромсдорф ГмбХ унд Ко.КГ Арцнаймиттель | Method and plaster for preventing and/or treating the cases of finger-nail dysfunction and/or growth disorders |
US20040234602A1 (en) | 2001-09-21 | 2004-11-25 | Gina Fischer | Polymer release system |
WO2003024430A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Morphine polymer release system |
WO2003026673A1 (en) | 2001-09-26 | 2003-04-03 | Vital Health Sciences Pty Ltd. | Modulation of vitamin storage |
AU2002951045A0 (en) | 2002-08-27 | 2002-09-12 | Vital Health Sciences Pty Ltd | Method of supplementing nascent endogenous storage forms |
JP4370451B2 (en) | 2001-09-28 | 2009-11-25 | 大塚製薬株式会社 | Pharmaceutical composition |
JP2003128531A (en) | 2001-10-17 | 2003-05-08 | Nonogawa Shoji Kk | Dermal external agent |
US20030144219A1 (en) | 2001-11-15 | 2003-07-31 | Phinney Stephen Dodge | Formulations and methods for treatment or amelioration of inflammatory conditions |
WO2003049774A1 (en) | 2001-12-13 | 2003-06-19 | Vital Health Sciences Pty Ltd | Transdermal transport of compounds |
IL162614A0 (en) | 2001-12-19 | 2005-11-20 | Res Dev Foundation | Liposomal delivery of vitamin e based compounds |
DE10200578A1 (en) | 2002-01-09 | 2003-07-10 | Roehm Gmbh | Adhesive and binding agents for dermal or transdermal therapy systems |
WO2003063860A1 (en) | 2002-01-31 | 2003-08-07 | Kansai Technology Licensing Organization Co., Ltd. | Compositions for preventing human cancer and method of preventing human cancer |
WO2003068209A1 (en) | 2002-02-14 | 2003-08-21 | Sonus Pharmaceuticals, Inc. | Metformin salts of lipophilic acids |
US7074825B2 (en) | 2002-03-07 | 2006-07-11 | Huanbiao Mo | Composition and method for treating cancer |
CN1652746A (en) | 2002-05-09 | 2005-08-10 | 昭和电工株式会社 | Skin whitening external preparation |
EP1507813A4 (en) | 2002-05-20 | 2005-11-23 | Ranbaxy Lab Ltd | Fat binding using inter-polymer complex of glucosamine and polyacrylic acid |
US20040018237A1 (en) | 2002-05-31 | 2004-01-29 | Perricone Nicholas V. | Topical drug delivery using phosphatidylcholine |
CA2494297C (en) | 2002-07-29 | 2011-10-18 | Transform Pharmaceuticals, Inc. | Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
AU2002950713A0 (en) | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
US20040067890A1 (en) | 2002-10-04 | 2004-04-08 | Gupta Shyam K. | Ascorbic acid salts of organic bases with enhanced bioavailability for synergictic anti-aging and skin protective cosmetic compositions |
FR2846651B1 (en) | 2002-10-30 | 2006-06-16 | Rhodia Polyamide Intermediates | PROCESS FOR PRODUCING CARBOXYLIC ACIDS |
US7399784B2 (en) | 2002-11-26 | 2008-07-15 | Children's Hospital & Research Center At Oakland | Tocopherol and tocotrienol anti-obesity medicaments |
US6645514B1 (en) | 2002-12-19 | 2003-11-11 | Access Business Group International, Llc | Increasing skin cell renewal with water-soluble Vitamin E |
EP1578325B1 (en) | 2002-12-31 | 2011-04-27 | Transdermal Biotechnology, Inc. | Stable topical drug delivery compositions |
KR20050086954A (en) | 2003-01-17 | 2005-08-30 | 바이탈 헬스 사이언시즈 피티와이 리미티드 | Compounds having anti-proliferative properties |
US7033998B2 (en) | 2003-04-11 | 2006-04-25 | All Natural Fmg, Inc. | Alcohol-free transdermal insulin composition and processes for manufacture and use thereof |
AU2003901812A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphates of secondary alcohols |
AU2003901813A0 (en) | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Pharmaceutical derivatives |
AU2003901815A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphate derivatives |
US20050152858A1 (en) | 2003-07-11 | 2005-07-14 | Isp Investments Inc. | Solubilizing agents for active or functional organic compounds |
US8546453B2 (en) | 2003-08-14 | 2013-10-01 | Rensheng Zhang | Propofol compositions and methods for reducing pain associated with propofol injection |
JP2006199589A (en) | 2003-09-03 | 2006-08-03 | Ltt Bio-Pharma Co Ltd | Nanoparticle containing physiologically active protein or peptide, method for producing the same and external preparation comprising the nanoparticle |
CN100536845C (en) | 2003-09-23 | 2009-09-09 | 中国医学科学院药物研究所 | Loratadine paster of penetrating skin |
US7207669B2 (en) | 2003-12-19 | 2007-04-24 | Arizona Chemical Company | Jet printing inks containing polymerized fatty acid-based polyamides |
CA3031283A1 (en) | 2004-01-22 | 2005-08-04 | University Of Miami | Topical co-enzyme q10 formulations and methods of use |
NZ549016A (en) | 2004-02-13 | 2012-03-30 | Bioavailability Inc | A microemulsion preparation of high concentration propofol for anesthetic uses |
PT2351555T (en) | 2004-02-23 | 2016-11-29 | Euro Celtique Sa | Abuse resistance opioid transdermal delivery device |
WO2005084678A1 (en) | 2004-03-03 | 2005-09-15 | Vital Health Sciences Pty Ltd | Alkaloid formulations |
DE602005020638D1 (en) | 2004-06-29 | 2010-05-27 | Japan Science & Tech Agency | SELECTIVE CULTURING METHOD AND SEPARATION METHOD FOR SMALL HEPATOCYTES USING HYALURONIC ACID |
KR101238703B1 (en) | 2004-08-03 | 2013-03-04 | 바이탈 헬스 사이언시즈 피티와이 리미티드 | Carrier for enteral administration |
JP4523388B2 (en) | 2004-11-19 | 2010-08-11 | 日本メナード化粧品株式会社 | Collagen synthesis promoter and skin external preparation |
US20060120979A1 (en) | 2004-12-02 | 2006-06-08 | Joel Rubin | Skin care composition comprising hydroquinone and a substantially anhydrous base |
CA2599424A1 (en) | 2005-03-03 | 2006-09-08 | Vital Health Sciences Pty Ltd | Compounds having anti-cancer properties |
CN101132789A (en) | 2005-03-03 | 2008-02-27 | 生命健康科学有限公司 | Compounds having lipid lowering properties |
US20090239827A1 (en) | 2005-03-03 | 2009-09-24 | Esra Ogru | Compounds having lipid lowering properties |
US20060228395A1 (en) | 2005-04-11 | 2006-10-12 | Robert Lamb | Vitamin E phosphate/phosphatidylcholine liposomes to protect from or ameliorate cell damage |
KR20080019228A (en) | 2005-06-17 | 2008-03-03 | 바이탈 헬스 사이언시즈 피티와이 리미티드 | A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
KR100764679B1 (en) | 2005-07-22 | 2007-10-09 | 익수제약 주식회사 | Patches comprising paroxetine for transdermal application |
US20070110739A1 (en) | 2005-11-11 | 2007-05-17 | Logsdon Lawrence M | Wipe away pain |
US7446096B2 (en) | 2005-12-19 | 2008-11-04 | Industrial Technology Research Institute | Glutathione based delivery system |
TW200800223A (en) | 2005-12-21 | 2008-01-01 | Shire Pharmaceuticals Inc | Transdermal delivery of meptazinol |
CA2631653A1 (en) | 2005-12-23 | 2007-06-28 | Vital Health Sciences Pty Ltd. | Compounds having cytokine modulating properties |
DE102006023336A1 (en) | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-diphenyl-pyrazoles II |
WO2008034178A1 (en) | 2006-09-21 | 2008-03-27 | Salvatore Iemma | Topical depilating composition |
RU2373957C2 (en) | 2006-10-13 | 2009-11-27 | Александр Метталинович Тишин | Therapeutic and diagnostic drug and biologically active substance carrier and application thereof for making drugs and method of regulated controlled drug or biologically active substance delivery with regulated desorption |
RU2009125613A (en) | 2006-12-05 | 2011-01-20 | Новартис АГ (CH) | MICROEMULSION MEDICINAL FORMS OF VALSARTAN AND METHODS FOR PRODUCING THEM |
IL181217A0 (en) | 2007-02-08 | 2007-07-04 | Haim Levy | Pharmaceuticalcompositions based on a microemulsion |
FR2921259B1 (en) | 2007-09-26 | 2015-02-13 | Lvmh Rech | COSMETIC USE OF TOCOPHEROL PHOSPHATE AS AN ANTI-AGING SKIN AGENT |
EP2113242A1 (en) | 2008-05-02 | 2009-11-04 | Pangaea Laboratories Limited | Antioxidant for use in cosmetic, medicated and pharmaceutical preparations |
US20090297591A1 (en) | 2008-05-30 | 2009-12-03 | Orient Pharma Co., Ltd. | Compositions And Methods For The Transdermal Delivery Of Pharmaceutical Compounds |
AR072008A1 (en) | 2008-06-13 | 2010-07-28 | Merck & Co Inc | HETEROBICICLIC COMPOUNDS AS QUINASA P38 INHIBITION AGENTS |
US20090319191A1 (en) | 2008-06-24 | 2009-12-24 | Rivas Ariel L | Method for diagnosis of an infectious disease stage and determination of treatment |
CN101524330B (en) | 2009-04-20 | 2013-01-09 | 重庆莱美药业股份有限公司 | Micro emulsion drug carrying system and manufacturing method thereof |
US20120202780A1 (en) | 2009-12-23 | 2012-08-09 | Paul David Gavin | Carrier composition |
RU2012133467A (en) | 2010-02-05 | 2014-02-10 | Фосфейдженикс Лимитед | CARRIER COMPOSITION |
AU2011213557B2 (en) | 2010-02-05 | 2015-05-07 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
JP5132700B2 (en) | 2010-02-22 | 2013-01-30 | 三菱電機株式会社 | Hand dryer |
CN102821791B (en) | 2010-03-30 | 2015-06-17 | 磷肌酸有限公司 | Transdermal delivery patch |
US9987226B2 (en) | 2010-12-10 | 2018-06-05 | Ns Technologies Pty Ltd | Methods for forming miniemulsions and use thereof for delivering bioactive agents |
CN102079756B (en) * | 2010-12-27 | 2012-09-12 | 锦州惠发天合化学有限公司 | Method for synthesizing perfluoroalkyl polyoxyethenyl phosphate fluorosurfactant |
EP2685992A4 (en) | 2011-03-15 | 2014-09-10 | Phosphagenics Ltd | Amino-quinolines as kinase inhibitors |
US9328317B2 (en) * | 2011-11-04 | 2016-05-03 | The Chemours Company Fc, Llc | Fluorophosphate surfactants |
CN102911203A (en) * | 2012-10-25 | 2013-02-06 | 浙江合诚化学有限公司 | Preparation method of alkyl phosphate |
KR101542541B1 (en) | 2014-10-07 | 2015-08-06 | 주식회사 대동요업 | The tile that prevention of countercurrent is possible |
CA3007587C (en) | 2015-12-09 | 2023-12-05 | Phosphagenics Limited | Pharmaceutical formulation |
-
2017
- 2017-12-13 BR BR112019012946A patent/BR112019012946A2/en active Search and Examination
- 2017-12-13 AU AU2017381395A patent/AU2017381395A1/en not_active Abandoned
- 2017-12-13 CN CN201780079206.XA patent/CN110662733A/en active Pending
- 2017-12-13 JP JP2019533107A patent/JP7198754B2/en active Active
- 2017-12-13 KR KR1020197021499A patent/KR102647670B1/en active IP Right Grant
- 2017-12-13 WO PCT/AU2017/051381 patent/WO2018112512A1/en active Application Filing
- 2017-12-13 US US16/470,943 patent/US20190330260A1/en not_active Abandoned
- 2017-12-13 MX MX2019006845A patent/MX2019006845A/en unknown
- 2017-12-13 EP EP17883017.0A patent/EP3558903A4/en active Pending
- 2017-12-13 CA CA3045702A patent/CA3045702A1/en active Pending
-
2019
- 2019-05-30 IL IL267006A patent/IL267006A/en unknown
-
2021
- 2021-12-15 US US17/552,188 patent/US11753435B2/en active Active
-
2022
- 2022-03-21 AU AU2022201954A patent/AU2022201954B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2022201954B2 (en) | 2023-12-21 |
KR102647670B1 (en) | 2024-03-15 |
RU2019119347A3 (en) | 2021-04-16 |
US11753435B2 (en) | 2023-09-12 |
JP2020502193A (en) | 2020-01-23 |
EP3558903A1 (en) | 2019-10-30 |
EP3558903A4 (en) | 2019-11-27 |
CN110662733A (en) | 2020-01-07 |
AU2022201954A1 (en) | 2022-04-14 |
IL267006A (en) | 2019-07-31 |
MX2019006845A (en) | 2019-10-15 |
KR20190100298A (en) | 2019-08-28 |
WO2018112512A1 (en) | 2018-06-28 |
US20220106353A1 (en) | 2022-04-07 |
CA3045702A1 (en) | 2018-06-28 |
JP7198754B2 (en) | 2023-01-04 |
AU2017381395A1 (en) | 2019-06-20 |
RU2019119347A (en) | 2021-01-22 |
BR112019012946A2 (en) | 2019-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0966476B1 (en) | Quinazolinone compounds | |
CA2574121A1 (en) | Antiviral compounds | |
WO2005087788A3 (en) | Methods for preparation of nucleoside phosphonate esters | |
JP4932995B2 (en) | Improved phosphorylation method and compounds produced by this method | |
US11753435B2 (en) | Process | |
CN102143967A (en) | Purification method for adefovir dipivoxil | |
KR20000022262A (en) | Steroid bisphosphonates | |
RU2788623C2 (en) | Method for phosphorylation of complex alcohol | |
EP1178994B1 (en) | Improved process for phosphorylation | |
Aneja et al. | The synthesis of a spin-labelled glycero-phospholipid | |
US20180303949A1 (en) | Water-soluble docetaxel anticancer drug compound and preparation method and use thereof | |
Tsubaki et al. | New phosphorylating agents for the synthesis of phosphatidylethanolamines | |
EP1370565B1 (en) | Method of producing 1-hydroxy-1,1-diphosphonic acid compounds | |
KR101882518B1 (en) | Process for preparing alkyl phosphates | |
Krylov et al. | Reactions of Chloroethynylphosphonates with 2-Aminoquinoline and 1-Aminoisoquinoline | |
DE102009046982A1 (en) | Solid-phase bound nucleosides | |
CA3185919A1 (en) | Phosphatidylalkanol homologues having labelled moieties | |
US9359389B2 (en) | Caged ceramide-1-phosphate derivatives | |
Wałejko et al. | Selective removal of phenyl group from alkyl diphenyl phosphates | |
KR20120083236A (en) | Process for preparing alkyl phosphates | |
KR20210121128A (en) | Method for preparing benzoazepine compounds | |
PL238317B1 (en) | Phosphone derivatives of decahydroquinoxaline and method for producing them | |
PL218060B1 (en) | New 3-ß-(1,2-diacyl-sn-glycero-3-phospho)-7α-hydroxy-androst-5-en-17-one and method of obtaining it | |
RU2014134383A (en) | OLIGONUCLEOTIDES WITH MODIFIED PHOSPHATE GROUP AND METHOD FOR PRODUCING THEM | |
PL190804B1 (en) | Method of obtaining active vitamin d metabolites and new intermediate compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AVECHO BIOTECHNOLOGY LIMITED, AUSTRALIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GEYTENBEEK, STEPHEN;STIRLING, ANDREW;GAVIN, PAUL DAVID;SIGNING DATES FROM 20190717 TO 20190731;REEL/FRAME:050044/0876 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |